Clinical aspects and treatment of systemic lupus erythematosus (SLE)
O1 JSLE and the NLRP3 inflammasome – a novel therapeutic target
Jo Gamble1, Michael W. Beresford2,3
1Child Health, Translational Medicine, University of Liverpool, Liverpool UK; 2Child Health, University of Liverpool, Liverpool, UK; 3Alder Hey Children's Hospital, Liverpool, UK
Correspondence: Jo Gamble
Big data analytics
O2 Persistence of CD4 memory pathogenic subsets in polyarticular juvenile idiopathic arthritis patients who relapse upon withdrawal of biologic therapy
Jing Yao Leong1, Joo Guan Yeo1,2, Phyllis Chen1, Liyun Lai1, Loshinidevi D/O Thana Bathi1, Justin Tan2, Thaschawee Arkachaisri2, 3, Daniel J. Lovell4,5, Salvatore Albani1,3
1Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singhealth, Singapore, Singapore; 2KK Women's and Children's Hospital, Singapore, Singapore; 3Duke-NUS Graduate Medical School, Singapore, Singapore; 4Division of Rheumatology, Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, United States; 5Department of Paediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Correspondence: Jing Yao Leong
O3 A multi-dimensional immunomics approach reveals distinct regulatory and antigen presenting B cell changes associated with childhood onset systemic lupus erythematosus
Joo Guan Yeo1,2, Jingyao Leong1, Thaschawee Arkachaisri2,3, Angela Yun June Tan2, Loshinidevi D/O Thana Bathi1, Xuesi Sim1, Phyllis Zi Xuan Chen1, Liyun Lai1, Lena Das2, Justin Hung Tiong Tan2, Elene Seck Choon Lee2, Yun Xin Book2, Salvatore Albani1,2,3
1Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore; 2KK Women's and Children's Hospital, Singapore, Singapore; 3Duke-NUS Graduate Medical School, Singapore, Singapore
Correspondence: Joo Guan Yeo
O4 Using blood transcriptomic data for disease etiology discovery in pediatric ANCA-associated vasculitis
Erin Gill1, Kelly Brown2, Kim Morishita2, David A. Cabral2, Robert E. W. Hancock1
1University of British Columbia, Vancouver, Canada; 2BC Children's Hospital, Vancouver, Canada
Correspondence: Erin Gill
Remission and outcome of systemic lupus erythematosus (SLE)
O5 Impact of fatigue, depressive symptoms and skin symptoms in adults with childhood-onset sle and the relation with HRQoL – the CHILL-NL study
Ayse Kaynak1, Noortje Groot1,2, Santusja Ramnath1, Marc Bijl3, Radboud Dolhain4, Onno Teng5, Els Zirkzee6, Karina de Leeuw7, Ruth Fritsch-Stork8, Irene Bultink9, Sylvia Kamphuis1 and on behalf of the CHILL-NL study group
1Department of Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Centre, Rotterdam, Netherlands; 2Department of Pediatric Immunology, Wilhemina Children’s Hospital – University Medical Centre Utrecht, Utrecht, Netherlands; 3Department of Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands; 4Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands; 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; 6Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands; 7Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands; 8Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands; 9Amsterdam Rheumatology and Immunology Center, Location VUmc, Amsterdam, Netherlands
Correspondence: Ayse Kaynak
O6 Clinical predictors of developing lupus nephritis in children
Eve M. Smith1, Peng Yin2, Andrea L. Jorgensen2, Michael W. Beresford1
1Department of Women and Children’s Health, Institute of Translational Medicine, Liverpool, United Kingdom; 2Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
Correspondence: Eve M. Smith
Immunometabolomics
O7 NRF2 enhances metabolic turnover in myeloid cells resulting in expansion of CD11b+Gr-1+MDSCs
Kim Ohl, Patricia Klemm, Klaus Tenbrock
Dept Of Pediatrics, RWTH University of Aachen, Aachen, Germany
Correspondence: Kim Ohl
O8 Novel serum broad-based proteomic discovery analysis identifies proteins and pathways dysregulated in juvenile dermatomyositis (JDM)
Hanna Kim1, Angélique Biancotto2, Foo Cheung2, Terrance O’Hanlon3, Ira Targoff 4, Yan Huang5, Frederick W. Miller3, Raphaela Goldbach-Mansky5, Lisa Rider3
1NIAMS, National Institutes of Health, Bethesda, MD, United States; 2CHI, NHLBI; 3EAG, NIEHS, National Institutes of Health, Bethesda, MD, United States; 4Oklahoma University (OUHSC) and Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, United States; 5TADS, NIAID, National Institutes of Health, Bethesda, MD, United States
Correspondence: Hanna Kim
Autoinflammatory diseases in practice
O9 A web-based collection of genotype-phenotype correlations in hereditary periodic fevers from the Eurofever registry
Riccardo Papa1, Matteo Doglio1, Helen J. Lachmann2, Seza Ozen3, Joost Frenkel4, Anna Simon5, Benedicte Neven6, Jasmin Kuemmerle-Deschner7, Huri Ozdogan8, Roberta Caorsi1, Silvia Federici1, Martina Finetti1, Nicolino Ruperto1, Isabella Ceccherini9, Marco Gattorno1 and the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Project
1UO Pediatria II-Reumatologia, Istituto Giannina Gaslini, Genoa, Italy; 2National Amyloidosis Centre, Royal Free Campus, University College Medical School, London, United Kingdom; 3Department of Pediatric Nephrology and Rheumatology, Hacettepe University, Ankara, Turkey; 4Department of Paediatrics, University Medical Center Utrecht, Utrecht, Netherlands; 5Department of General Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 6Unité d'immuno-hématologie pédiatrique, Hôpital Necker Enfants Malades, Paris, France; 7Paediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany; 8Ic Hastaliklari ABD, Romatoloji BD, Cerrahpasa Tip Fakultesi, Istanbul, Turkey; 9Laboratory of Molecular Genetics, Istituto Giannina Gaslini, Genoa, Italy
Correspondence: Riccardo Papa
Genetic aspects of pediatric rheumatic diseases
O10 IKZF1 mutation underlines the B cell landscape heterogeneity in mendelian lupus
Cécile Frachette1, Sulliman O. Omarjee1, Anne Laure Mathieu1, Thibault Andrieu2, Paul Mondier3, Gillian Rice4, Heloïse Reumaux5, David Launay6, Marc Lambert7, Guillaume Lefevre8, Nicole Fabien9, Christophe Malcus10, Isabelle Rouvet11, Emilie Chopin11, Anne-Sophie Michallet3, Thierry Defrance3, Thierry Walzer1, Yanick Crow12, Alexandre Belot1
1Inserm U1111, Centre International de Recherche en Infectiologie- International Center for Infectiology Research, LYON, France; 2Inserm SFR Biosciences Gerland, LYON, France; 3Centre International de Recherche en Infectiologie- International Center for Infectiology Research, LYON, France; 4Division of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; 5Rhumatologie médecine interne pédiatrique, Urgences, Pédiatrie générale et maladies infectieuses Hôpital Salengro, Lille, France; 6Department of Internal medicine and Clinical Immunology, UMR 995 Inserm, University of Lille, Lille, France; 7Service de médecine interne, Hôpital Huriez, Lille, France; 8Lille Inflammation Research International center, Lille, France; 9Service d'immunologie, CHU de Lyon HCL-Groupement Hospitalier Sud, Lyon, France; 10Laboratoire d'immunologie cellulaire, Groupement hospitalier Edouard herriot, Lyon, France; 11Biotechnology Department, Hospices civils de Lyon, Lyon, France; 12Inserm UMR 1163, Laboratory of Neurogenetics and Neuroinflammation, Paris, France
Correspondence: Cécile Frachette
Remission in chronic arthritis
O11 Development of New JADAS and cJADAS cut-offs for disease activity states in oligoarthritis and rf-negative polyarthritis from a large multinational cohort of children with juvenile idiopathic arthritis
Alessandro Consolaro1,2, E.H. Pieter van Dijkhuizen3, Graciela Espada4, Boriana Varbanova4, Sheila K. Oliveira4, Paivi Miettunen4, Gaelle Chédeville4, Michael Hofer4, Pavla Dolezalova4, Ivan Foeldvari4, Gerd Horneff4, Anne Estmann4, Chris Pruunsild4, Rosa Merino4, Inmaculada Calvo Penades4, Pablo Mesa-del-Castillo4, Pekka Lahdenne4, Maka Ioseliani4, Maria Trachana4, Olga Vougiouka4, Miroslav Harjacek4, Ilonka Orban4, Tamàs Constantin4, Nahid Shafaie4, Violeta Panaviene4, Marite Rygg4, Elzbieta Smolewska4, Jose Antonio Melo-Gomes4, Jelena Vojinovic4, Ekaterina Alekseeva4, Tadej Avcin4, Veronika Vargova4, Nuray Aktay Ayaz4, Ozgur Kasapcopur4, Yaryna Boyko4, Sarah Ringold4, Marco Garrone1,4, Nicolino Ruperto1,4, Angelo Ravelli1,2 on behalf of PRINTO and EPOCA Study Group
1Istituto Giannina Gaslini, Genova, Italy; 2University of Genova, Genova, Italy; 3Wilhelmina Children's Hospital, Utrecht, Netherlands; 4PRINTO, Genova, Italy
Correspondence: Alessandro Consolaro
JADAS10 | JADAS27 | JADAS71 | cJADAS10 | cJADAS27 | cJADAS71 | |
---|---|---|---|---|---|---|
Oligoarthritis | ||||||
Remission | 1.5 | 1.5 | 1.5 | 1.2 | 1.2 | 1.2 |
LDA | 3.9 | 3.7 | 3.9 | 3.4 | 3.3 | 3.4 |
HDA | 16.4 | 16.2 | 16.4 | 14.3 | 14.1 | 14.3 |
Polyarthritis | ||||||
Remission | 2.6 | 2.6 | 2.6 | 2.4 | 2.3 | 2.4 |
LDA | 5.1 | 4.9 | 5.1 | 5.1 | 4.9 | 5.1 |
HDA | 18.9 | 18.9 | 22.7 | 19.0 | 20.0 | 25.3 |
New insights into the pathogenesis of systemic lupus erythematosus (SLE)
O12 Interferon-γ plays a role in the pathogenesis of pediatric systemic lupus erythematosus and its activity correlates with disease activity
Gian Marco Moneta1, Claudia Bracaglia1, Ivan Caiello1, Luisa Bracci-Laudiero1,2, Rita Carsetti3, Fabrizio De Benedetti1, Emiliano Marasco1
1Division of Rheumatology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy; 2Institute of Translational Pharmacology, CNR, Rome, Italy; 3B Cell Physiopathology Unit, Immunology Research Area, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
Correspondence: Marco Moneta
Scleroderma and related disorders
O13 Reliability and performance of the loscat clinical score for the assessment of activity and tissue damage in a large cohort of patients with juvenile localized scleroderma
Anna Agazzi, Gloria Fadanelli, Fabio Vittadello, Francesco Zulian, Giorgia Martini
Department of Woman and Child Health, University of Padua, Padova, Italy
Correspondence: Anna Agazzi
O14 Tocilizumab is a promising treatment option for therapy resistent juvenile localised scleroderma patients
Ivan Foeldvari1, Jordi Anton2, Mark Friswell3, Blanca Bica4, Jaime de Inocencio5, Angela Aquilani6, Nicola Helmus1
1Hamburg Center for Pediatric and Adolescent Rheumatology, AM Schöen Klinik Eilbek, Hamburg, Germany; 2Sant Joan de Déu Hospital, Barcelona, Spain; 3Great North Children’s Hospital, Newcastle, United Kingdom; 4Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 5University Hospital 12 de Octubre, Madrid, Spain; 6Ospedale Bambino Gesù, Rome, Italy
Correspondence: Ivan Foeldvari
Pathogenesis of juvenile idiopathic arthritis (JIA)
O15 P75NTR/PRONGF up regulation in synovial tissues activates inflammatory responses in chronic arthritis patients
gaetana minnone1, Melissa Noack2, Pierre Miossec3, Ivan Caiello1, Marzia Soligo4, Luigi Manni4, Antonio Manzo5, Fabrizio De Benedetti1, Luisa Bracci-Laudiero4
1Division of Rheumatology and Immuno-Rheumatology Research Laboratories, Bambino Gesù Children’s Hospital, Rome, Italy; 23 Immunogenomics and Inflammation Research Unit, EA 4130, Edouard Herriot Hospital, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, France; 3Immunogenomics and Inflammation Research Unit, EA 4130, Edouard Herriot Hospital, Hospices Civils de Lyon and University Claude Bernard Lyon 1,, Lyon, France; 4Institute of Translational Pharmacology, CNR, Rome, Italy; 5Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology,, IRCCS Policlinico S. Matteo Foundation/University of Pavia, Pavia, Italy
Correspondence: gaetana minnone
Oral Presentations 1
O16 Three treatment strategies in recent onset dmard naive juvenile idiopathic arthritis: first results of clinical outcome after 24 months
Petra Hissink Muller1,2, Danielle Brinkman1,3, Dieneke Schonenberg4, Wytse van den Bosch1, Yvonne Koopman-Keemink5, Isabel Brederije1, Peter Bekkering6, Taco Kuijpers4, Marion van Rossum7, Lisette W. van Suijlekom-Smit8, J M. van den Berg4, Stefan Boehringer9, C F. Allaart10, Rebecca ten Cate1
1Pediatric Rheumatology, LUMC, Leiden, Netherlands 2Pediatric Rheumatology, Erasmus MC Sophia, Rotterdam, 3Pediatrics, Alrijne Hospital, Leiderdorp, Netherlands 4Department of Pediatric Hematology, Immunology, Rheumatology and Infectious Diseases, Emma Children’s Hospital AMC, University of Amsterdam, Amsterdam, Netherlands 5Pediatrics, Juliana Children's Hospital, The Hague, Netherlands 6Pediatric Oncology, Princess Máxima Center of Pediatric Oncology, Utrecht, Netherlands 7Pediatric Rheumatology, Amsterdam Rheumatology and Immunology Center location Reade, Amsterdam, Netherlands 8Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands 9Medical Statistics and Bioinformatics, LUMC, Leiden, Netherlands 10Rheumatology, LUMC, Leiden, Netherlands
Correspondence: Petra Hissink Muller
Arm 1 n = 31 | Arm 2 n = 32 | Arm 3 n = 29 | 3 vs 1 p OR (CI) | 2 vs 1 p OR (CI) | 3 vs 2 p OR (CI) | |
---|---|---|---|---|---|---|
ACRPEdi30(%)(CI) | 92.2 (82,1-102.4) | 84.4 (71.2-97.5) | 96.6 (89.8-103.3) | 0.1 1.7 (0.8-3.4) | 0.8 0.9(0.5-1.7) | 0.1 0.9-3.7 |
ACRPedi50 (%)(CI) | 85.5 (72.4-98.6) | 83.8 (70.1-97.4) | 93.1 (83.7-102.4) | 0.3 1.4(0.7-2.8) | 0.9 1.1(0.6-2.0) | 0.4 1.3(0.7-2.7) |
ACRPedi70 (%)(CI) | 69.0 (52.1-85.9) | 68.8 (51.6-85.9) | 82.8 (68.8-96.8) | 0.07 1.8(1.0-3.3) | 0.7 0.9(0.4-1.7) | 0.03 2.1(1.1-4.0) |
Inactive disease (%) | 61.0 (39.7-82.3) | 63.1 (43.6-82.7) | 61.0 (40.9-81.2) | 0.9 1.0(0.7-1.7) | 0.1 0.7(0.4-1.1) | 0.09 1.5(0.9-2.5) |
JADAS-10 (CI) | 2.6(1.4-3.8) | 4.0(2.2-5.8) | 3.0(1.6-4.4) | 0.6 0.6(0.1-3.5) | 0.2 3.1(0.5-20.3) | 0.09 0.2(0.03-1.3) |
O17 Predictive value of magnetic resonance imaging in patients with juvenile idiopathic arthritis in clinical remission
Marta Mazzoni1, Angela Pistorio2, Stefania Viola3, Alessia Urru1, Emanuela Sacco3, Eleonora Zaccheddu3, Francesca Magnaguagno4, Angelo Ravelli1, Alberto Martini1, Clara Malattia1
1Università degli studi di Genova, Pediatria II-Reumatologia, Genoa, Italy; 2Epidemiologia, Biostatistica e Comitati, Genoa, Italy; 3Pediatria II-Reumatologia, Genoa, Italy; 4Radiologia, G. Gaslini, Genoa, Italy
Correspondence: Marta Mazzoni
O18 Baseline predictors of functional disability eight years after disease onset in the nordic juvenile idiopathic arthritis population-based cohort
Veronika Rypdal1, Ellen D Arnstad2, Lillemor Berntson3, Marek Zak4, Kristiina Aalto5, Suvi Peltoniemi5, Susan Nielsen4, Mia Glerup6, Troels Herlin6, Anders Fasth7, Maria Ekelund8, Marite Rygg2, Ellen Nordal1 and Nordic Study Group of Pediatric Rheumatology (NoSPeR)
1Dep of Pediatrics, University Hospital of North Norway, UiT The Arctic University of Norway, Tromsø; 2Dep of Laboratory Medicine, Children’s and Women’s Health, NTNU, Dep of Pediatrics, St.Olavs Hospital, Trondheim, Norway; 3Dep of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden; 4Pediatric Clinic II, Rigshospitalet, Copenhagen, Denmark; 5Dep of Pediatrics, Helsinki University Hospital, Helsinki, Finland; 6Dep of Pediatrics, Århus University Hospital, Århus, Denmark; 7Dep of Pediatrics, University of Gothenburg, Gothenburg, Sweden; 8Dep of Pediatrics, Ryhov County Hospital, Dep of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
Correspondence: Veronika Rypdal
Clinical Characteristics | N | CHAQ/HAQ =0 | CHAQ/HAQ >0 | OR (95%CI) | p |
---|---|---|---|---|---|
Cumulative active joint count | 352 | 3 (1-6) | 5 (2-9) | 1.1 (1.0-1.1) | 0.001 |
Physician GA, VAS | 210 | 1.0 (0.3-2.0) | 2.0 (0.7-4.3) | 2.5 (1.5-4.0) | < 0.001 |
Symmetric wrist arthritis, n (%) | 351 | 28 (50.0) | 28 (50.0) | 2.5 (1.4-4.5) | 0.002 |
Symmetric finger arthritis, n (%)* | 351 | 20 (39.2) | 31 (60.8) | 4.2 (2.3-7.8) | < 0.001 |
Symmetric ankle arthritis, n (%) | 351 | 50 (57.5) | 37 (42.5) | 1.9 (1.1-3.1) | 0.02 |
CHAQ- score at baseline | 239 | 0.1 (0.0-0.9) | 0.6 (0.0-1.4) | 2.0 (1.4-3.0) | 0.001 |
Patient/parent GA, VAS | 234 | 0.7 (0.0-2.3) | 2.0 (1.0-4.0) | 2.3 (1.5-3.6) | < 0.001 |
Pain VAS | 231 | 0.7 (0.0-2.3) | 2.7 (1.0-5.0) | 3.2 (2.0-5.0) | < 0.001 |
Morning stiffness > 15 min, n (%) | 276 | 41 (41.4) | 58 (58.6) | 5.2 (3.0-8.9) | <0.001 |
O19 What is the outcome of juvenile idiopathic arthritis in adulthood? The monocentric experience of 414 patients followed in a transition tertiary clinic of rheumatology
Irene Pontikaki1,2,3, Lorenza Maria Argolini4, Tania Ubiali4, Maria Gerosa2,3, Carolina Artusi4, Marcello Truzzi5, Roberto Viganò6, Antonella Murgo2,3, Orazio De Lucia2,3, Pierluigi Meroni2,3
1Center of Pediatric Rheumatology, Milan, Italy; 2Rheumatology, ASST Pini/CTO, Milan, Italy; 3Chair of Rheumatology, Milan, Italy; 4Rheumatology, University of Milan, Milan, Italy; 5Rheuma Surgery, Milan, Italy; 6Division of Rheumatoid Arthritis Surgery, ASST Pini/CTO, Milan, Italy
Correspondence: Irene Pontikaki
O20 Identification of novel antibodies predictive of the development of uveitis in jia using high-density nucleic acid programmable protein arrays
Madeleine Rooney1, David Gibson2, Ji Qui3, Sorcha Finnegan1, Joshua Labaer3
1Center Experimental Medicine, Queens University Belfast, Belfast, United Kingdom; 2NI Centre of Stratified Medicine, Ulster University, Londonderry, United Kingdom; 3Center for Personalized Diagnostics, Arizona State University, Tempe, AZ United States
Correspondence: David Gibson
O21 New onset uveitis in patients with juvenile idiopathic arthritis under biological therapy
Irina Nikishina1, Olga Kostareva1, Maria Kaleda1, Svetlana Rodionovskaya1, Svetlana Arsenyeva1, Anna Shapovalenko1, Ekaterina Denisova2
1Pediatric, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 2Pediatric, Helmgoltz Moscow Research Institute of Eye Diseases, Moscow, Russian Federation
Correspondence: Irina Nikishina
O22 Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody – associated vasculitis
Milena Kostić1, Fariborz Mobarrez2, Jelena Vojinović1, Iva Gunnarsson2, Aleksandra Antović2
1Department of Pediatrics, Clinical Center, Nis, Serbia; 2Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Correspondence: Milena Kostić
Active AAV | Inactive AAV | Healthy controls | p-value (respectively) | ||||
---|---|---|---|---|---|---|---|
median | IQR | median | IQR | median | IQR | ||
Tissue factor | 265 | 247 | 174 | 107 | 105 | 84,5 | p < 0.01* p < 0.001**
|
NETs | 112 | 24 | 103 | 18 | 44 | 35 | p < 0.05* p < 0.0001** p < 0.001***
|
Pentraxin3 | 1332 | 1810 | 347 | 294,5 | 184 | 146,5 | p < 0.01* p < 0.0001** ns***
|
HMGB1 | 684 | 452,5 | 380 | 258 | 77 | 61,5 | p < 0.01* p < 0.001** p < 0.001***
|
TWEAK | 131 | 83 | 141 | 102,5 | 67 | 53 | ns* p < 0.0001** p < 0.05***
|
Plasminogen | 86 | 23 | 89 | 23 | 44 | 33,5 | ns* p < 0.001** p < 0.01***
|
C3a | 201 | 91 | 147 | 87 | 89 | 72 | ns* p < 0.001** p < 0.05***
|
C5a | 131 | 86,5 | 111 | 65 | 51 | 30 | ns* p < 0.001** p < 0.01***
|
O23 Plasmalemma vesicle-associated protein 1 (pv-1) as a marker of active disease in childhood vasculitis.
Andrea Taddio1, Sarah Abu Rumeileh2, Claudia Bracaglia3, Luigina De Leo4, Rebecca Nicolai3, Fabrizio De Benedetti3, Alberto Tommasini4, Samuele Naviglio4, Serena Pastore4, Alessandro Ventura1, Tarcisio Not1
1Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" - and University of Trieste, Trieste, Italy; 2University of Trieste, Trieste, Italy; 3Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; 4Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" -, Trieste, Italy
Correspondence: Andrea Taddio
Patients | Controls N = 62 | Acute Vasculitis N = 35 | Remission vasculitis N = 9 |
---|---|---|---|
PV – 1 (ng/ml) Median (interquartile range) | 0.221 (0.082 – 0.436) | 1.818 (0.746– 3.970) | 0.316 (0.203 – 0.606) |
p value | < 0.001 | < 0.001 |
O24 Takayasu arteritis in childhood: retrospective experience from a tertiary referral center in South India
Sathish Kumar1, Ruchika Goel2, Debashish Danda2
1Pediatric Rheumatology, Department of Pediatrics, Christian Medical College, Vellore, India; 2Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India
Correspondence: Sathish Kumar
Oral Presentations 2
O25 Single cell RNA-sequencing of bone marrow macrophages identifies a distinct subpopulation in systemic JIA with features of interferon response, endocytic vesicles and phagocytosis
Grant Schulert1, Nathan Salomonis2, Sherry Thornton1, Alexei Grom1
1Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; 2Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
Correspondence: Grant Schulert
O26 Adjudication of infections from the pharmacovigilance in juvenile idiopathic arthritis patients (pharmachild) treated with biologic agents and/or methotrexate with a focus on opportunistic infections
Gabriella Giancane, Joost Swart, Elio Castagnola, Andreas Groll, Gerd Horneff, Hans-Iko Huppertz, Dan Lovell, Tom Wolfs, Michael Hofer, Ekaterina Alexeeva, Violeta Panaviene, Susan Nielsen, Jordi Anton, Florence Uettwiller, Valda Stanevicha, Maria Trachana, Fabrizio De Benedetti, Constantin Ailioaie, Elena Tsitsami, Sylvia Kamphuis, Troels Herlin, Pavla Dolezalova, Gordana Susic, Berit Flato, Flavio Sztajnbok, Elena Fueri, Francesca Bovis, Francesca Bagnasco, Angela Pistorio, Alberto Martini, Nico Wulffraat, Nicolino Ruperto
Pediatria II, Reumatologia; PRINTO, Istituto Giannina Gaslini, GENOA, Italy
Correspondence: Gabriella Giancane
HLT | N | % |
---|---|---|
Herpes viral infections | 265 | 38.9 |
Lower and upper respiratory tract and lung infections | 93 | 13.6 |
Epstein-Barr viral infections | 38 | 5.6 |
Abdominal and gastrointestinal infections | 32 | 4.7 |
Tuberculous infections | 29 | 4.3 |
Candida infections | 17 | 2.5 |
Influenza viral infections | 14 | 2.1 |
Streptococcal infections | 14 | 2.1 |
Salmonella infections | 9 | 1.3 |
O27 Use of whole-body magnetic resonance to identify potential diagnostic clues in children with fever of unknown origin (FUO)
Sara Signa1, Giorgio Stagnaro2, Roberta Caorsi1, Francesca Minoia1, Paolo Picco1, Angelo Ravelli1, Gian Michele Magnano2, Maria Beatrice Damasio2, Marco Gattorno1
1U.O. Pediatria II, Instituto Giannina Gaslini, Genova, Italy; 2U.O. Radiologia, Instituto Giannina Gaslini, Genova, Italy
Correspondence: Sara Signa
O28 Usefulness of magnetic resonance imaging in early assesment of low back pain with possible inflammatory cause in children
Lovro Lamot1,2, Mandica Vidovic1, Matej Mustapic1, Mirta Lamot1, Ivana Rados1, Karla Rubelj1, Miroslav Harjacek1,2
1Clinical Hospital center Sestre Milosrdnice, Zagreb, Croatia; 2Univeristy of Zagreb School of Medicine, Zagreb, Croatia
Correspondence: Lovro Lamot
O29 Efficacy and safety of Canakinumab in patients with HIDS/MKD: results from the pivotal phase 3 cluster trial
Joost Frenkel1, Jordi Anton2, Philip Hashkes3, Marco Cattalini4, Tamas Constantin5, Avi Livneh6, Bernard Lauwerys7, Susanne Bensler8, Paivi Miettunen9, Tillman Kallinich10, Jasmin Kummerle-Deschner11, Yankun Gong12, Eleni Vritzali13, Guido Junge13, Fabrizio De Benedetti14, Anna Simon15
1University Medical Center Utrecht, Utrect, Netherlands; 2Hospital Sant Joan de Déu, Barcelona, Spain; 3Shaare Zedek Medical Center, Jerusalem, Israel; 4Pediatric Clinic, University of Brescia and Spedali Civili di Brescia, Brescia, Italy; 5Department of Pediatrics, Semmelweis Egyetem, Budapest, Hungary; 6Department of Medicine, Sheba Medical Centre, Tel-Hashomer, Ramat-Gan, Israel; 7Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium; 8Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada; 9Alberta Children’s Hospital Research Institute Calgary, Calgary, Canada; 10Charité, Humboldt University, Berlin, Germany; 11University Hospital Tuebingen, Tuebingen, Germany; 12Novartis Pharma, Shanghai, China; 13Novartis Pharma AG, Basel, Switzerland; 14IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy; 15Radboud University Medical Centre, Nijmegen, Netherlands
Correspondence: Joost Frenkel
PBO N = 35 | CAN 150 mg q4w N = 37 | p-value | |
---|---|---|---|
Proportion of responders at Wk 16 (E2), n (%) | 2 (5.7) | 13 (35.1) | <0.002* |
Proportion of patients with no new flare at Wk 40 (E3), n (%) | PBO N = 7 | CAN 150 mg q8w N = 6 | p-value |
1 (14.3) | 3 (50.0) | 0.2168 | |
Safety | |||
PBO N = 35 | Any CAN*, E2 N = 68 | Any CAN*, E2 + E3 N = 71 | |
Exposure to CAN, pyr | 3.2 | 19.1 | 51.0 |
Number of AEs (AE rate/100 pyr) | 59 (1818.5) | 251 (1313.6) | 613 (1201.2) |
Number of SAEs (SAE rate/100 pyr) | 4 (123.3) | 11 (57.6) | 20 (39.2) |
O30 Efficacy, safety, pharmacokinetics and pharmacodynamics of Canakinumab in patients with traps: results from the pivotal phase 3 cluster trial
Marco Gattorno1, Ryoki Hara2, Anna Shcherbina3, Laura Obici4, Segundo Bujan5, Gerd Hoerneff6, Anette Jansson7, Riva Brik8, Itzhak Rosner9, Alberto Tomassini10, Yankun Gong11, Eleni Vritzali12, Guido Junge12, Fabrizio De Benedetti13, Helen Lachmann14
1Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy; 2Yokohama City University, Yokohama, Japan; 3Clinical immunology Department, Center of Children's Hematology n.a. D. Rogachev, Moscow, Russian Federation; 4Amyloidosis Research and Treatment Centre, Biotechnology Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5Vall d'Hebron Hospital, Barcelona, Spain; 6Asklepios Clinic, Sankt Augustin, Munich, Germany; 7Department of Rheumatology & Immunology, Dr. von Hauner Childrens Hospital, Ludwig-Maximilians-University, Munich, Germany; 8Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel; 9Rheumatology, Bnai-Zion Medical Center, Rappaport Faculty of Medicine. Technion, Haifa, Israel; 10Institute for Maternal and Child Health- IRCCS “Burlo Garofolo”, Trieste, Italy; 11Novartis Pharma, Shanghai, China; 12Novartis Pharma AG, Basel, Switzerland; 13IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy; 14UK National Amyloidosis Centre, University College London, London, United Kingdom
Correspondence: Marco Gattorno
CAN 150 mg q4w N = 22 | PBO N = 24 | p-value | |
Proportion of responders at Wk 16 (E2), n(%) | 10 (45.5) | 2 (8.3) | 0.005* |
Proportion of patients with no new flare at Wk 40 (E3), n(%) | CAN 150 mg q8w N = 4 | PBO N = 5 | p-value |
3 (75.0) | 2 (40.0) | 0.3571 | |
Safety | |||
PBO (N = 24) | Any CAN*, E2 (N = 43) | Any CAN*, E2 + E3 (N = 61) | |
Exposure to CAN, pyr | 2.0 | 12.1 | 39.2 |
Number of AEs (AE rate/100 pyr) | 34 (1698.8) | 112 (925.7) | 265 (676.2) |
Number of SAEs (SAE rate/100 pyr) | 1 (50.0) | 3 (24.8) | 5 (12.8) |
O31 Evidence based recommendations for corticosteroid tapering/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial
Gabriella Giancane, Claudio Lavarello, Angela Pistorio, Francesco Zulian, Bo Magnusson, Tadej Avcin, Fabrizia Corona, Valeria Gerloni, Serena Pastore, Roberto Marini, Silvana Martino, Anne Pagnier, Michel Rodiere, Christine Soler, Valda Stanevicha, Rebecca Ten Cate, Yosef Uziel, Jelena Vojinovic, Elena Fueri, Angelo Ravelli, Alberto Martini, Nicolino Ruperto
Pediatria II, Reumatologia; PRINTO, Istituto Giannina Gaslini, GENOA, Italy
Correspondence: Gabriella Giancane
OR (95% CI) | P#
| |
---|---|---|
Responder at 2 months: Printo-50 (vs. not responder/Printo-20) | 5.41 (1.37 - 21.32) | 0.0076 |
Printo-70 (vs. not responder/Printo-20) | 6.90 (1.91 - 24.99) | |
Printo-90 (vs. not responder/Printo-20) | 4.46 (1.08 - 18.38) | |
Age at onset > 8.53 years (£ 8.53 years) | 4.64 (1.69 - 12.71) | 0.0017 |
Treatment group: PDN + MTX (vs. PDN/PDN + CSA) | 3.63 (1.30 - 10.09) | 0.0116 |
AUC of the model: 0.80 |
O32 Evaluation of varicella zoster immune status in children with rheumatic diseases treated with biologic agents
Elena Moraitis1,2, Lucy Backhouse1, Ian Macdonald1, Jennifer Crooks1, Muthana Al-Obaidi1
1Rheumatology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom; 2Infection, Inflammation, Rheumatology, UCL GOS Institute of child Health, London, United Kingdom
Correspondence: Elena Moraitis
O33 Prolonged reduced aerobic fitness in adolescents and young adults with juvenile idiopathic arthritis
Philomine Van Pelt1,2, Tim Takken3, Marco V. Brussel3, Radboud Dolhain4, Johannes Bijlsma5, Aike Kruize5, Nico Wulffraat1
1rheumatology and pediatric rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands; 2rheumatology and pediatric rheumatology, ErasmusMC University Rotterdam, Rotterdam, Netherlands; 3Child Development and Exercise Center, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands; 4rheumatology, ErasmusMC University Rotterdam, Rotterdam, Netherlands; 5rheumatology and immunology, University Medical Center Utrecht, Utrecht, Netherlands
Correspondence: Philomine Van Pelt
Autoinflammatory diseases
P1 PFAPA syndrome in large pediatric population: a single center experience
Esra Pehllivan, Amra Adrovic, Sezgin Sahin, Kenan Barut, Ovgu Kul, Ozgur Kasapcopur
Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
Correspondence: Amra Adrovic
Patients with coexistence of FMF (n = 63) | Patients without coexistence of FMF(n = 296) | p | |
---|---|---|---|
Mean age at disease onset (months ± SD) | 27 ± 23 | 22 ± 16.6 | 0.562 |
Mean age at diagnosis (months ± SD) | 44 ± 23 | 43 ± 21 | 0.274 |
Male/Female ratio | 36/27 | 168/128 | 1.0 |
Mean time interval between fever episodes (weeks ± SD) | 3 ± 0.9 | 3.2 ± 1.4 | 0.61 |
Mean duration of fever (days ± SD) | 3.6 ± 1.4 | 3.9 ± 3.6 | 0.94 |
Cryptic tonsillitis | 63 (100%) | 296 (100%) | 1.0 |
Abdominal pain | 20 (31.7%) | 83 (28%) | 0.54 |
Response to colchicum treatment | 18/27 (66%) | 6/18 (33%) | 0.03 |
Clinical response to surgical treatment | 18/36 (50%) | 113/146 (77.4%) | 0.002 |
P2 through new classification criteria for inherited periodic fevers and PFAPA. An integrated approach among clinicians and geneticists.
Silvia Federici1, Federica Vanoni2, Francesca Bovis3, Maria Pia Sormani3, Nicola Ruperto4, Marco Gattorno4 and on behalf of the Expert Committee for the Classification Criteria in periodic fever
12° Division of Pediatric, Gaslini Institute, Genova, Italy; 2Pediatric Rheumatology Unit, CHUV, University of Lausanne, Lausanne, Switzerland; 3Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 42° Division of Pediatric, Gaslini Institute, Genoa, Italy
Correspondence: Silvia Federici
P3 Chronic recurrent multifocal osteomyelitis: case report
Maria Francesca Gicchino1, Mario Diplomatico1, Daniela Capalbo1, Carmela Granato1, Alma Nunzia Olivieri1
1Department of Women, Child and General and Specialistic Surgery, Università della Campania Luigi Vanvitelli, Naples, Italy
Correspondence: Maria Francesca Gicchino
P4 Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages
Yuri Kawasaki1, Sanami Takada2, Naotomo Kambe3, Ryuta Nishikomori4, Tatsutoshi Nakahata1, Megumu K. Saito1
1Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan; 2Department of Dermatology, Chiba University Graduate School of Medicine, Chiba, Japan; 3Department of Dermatology, Kansai Medical University, Hirakata, Japan 4Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
Correspondence: Yuri Kawasaki
P5 Transcriptional regulatory gene variations could influence expression patterns and inflammatory propagation in clavicular cortical hyperostosis
Lovro Lamot1,2, Kristina Gotovac Jercic2, Antonela Blazekovic2, Mandica Vidovic1, Mirta Lamot1, Fran Borovecki2, MIroslav Harjacek1,2
1Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia; 2University of Zagreb School of Medicine, Zagreb, Croatia
Correspondence: Lovro Lamot
Gene | Variant | Coordinate | Transcript | Consequence | dbSNP ID |
---|---|---|---|---|---|
CTBP2 | T > T/A | 126727602 | rs76555439 | ||
HYDIN | GA > GA/G | 70896015 | NM_032821.2 | frameshift_variant, feature_truncation | rs77276171 |
ZNF717 | A > A/T | 75786827 | NM_001128223.1 | stop_gained | rs79635065 |
ZNF717 | C > C/A | 75786916 | NM_001128223.1 | stop_gained | rs78906544 |
ZNF717 | G > G/T | 75787127 | NM_001128223.1 | stop_gained | rs74740396, rs148624740 |
ZNF717 | T > T/TA | 75787352 | NM_001128223.1 | frameshift_variant, feature_elongation | |
ZNF717 | GAA > GAA/G | 75787645 | NM_001128223.1 | frameshift_variant, feature_truncation | rs67117547, rs141065192 |
ZNF717 | G > G/C | 75788028 | NM_001128223.1 | stop_gained | rs77971486, rs150689808 |
P6 A novel phenotype associated with ADAM17 mutations
Sonia Melo Gomes1,2, Ebun Omoyinmi1, Ying Hong1, Glenn Anderson3, William Mufzud3, William Moore4, Clive Edelsten4, Louise Wilson5, Paul Brogan2
1Rheumatology, GOSH UCL Institute of Child Health, London, United Kingdom; 2Rheumatology, Great Ormond Street Hospital, London, United Kingdom; 3Pathology, Great Ormond Street Hospital, London, United Kingdom; 4Ophthalmology, Great Ormond Street Hospital, London, United Kingdom; 5Genetics, Great Ormond Street Hospital, London, United Kingdom
Correspondence: Sonia Melo Gomes
P7 The impact of gastrointestinal clinical manifestations in autoinflammatory diseases (AID): lessons from the international Eurofever registry
Alessia Omenetti1, Francesca Bovis2, Joost Frenkel3, Helen J. Lachmann4, Seza Ozen5, Nicolino Ruperto6, Marco Gattorno6 on behalf of PRINTO and Eurofever Registry
1DINOGMI, Genoa, Italy; 2Biostatistics Unit, Department of Health Sciences,, University of Genoa, Genoa, Italy; 3University Medical Center Utrecht, Utrecht, Netherlands; 4Division of Medicine, University College London, London, United Kingdom; 5Department of Paediatric Rheumatology, Hacettepe University, Ankara, Turkey; 6Pediatria II, Gaslini IRCCS, Genoa, Italy
Correspondence: Alessia Omenetti
n= | LC1 | LC2 | LC3 | LC4 | Tot GI Cohort | Total not GI Cohort | Total AID |
---|---|---|---|---|---|---|---|
Total | 87 | 52 | 666 | 61 | 866 | 789 | 1655 |
CAPS | 4 | 7 | 31 | 2 | 44 | 134 | 179 |
CRMO | 0 | 0 | 28 | 1 | 29 | 323 | 352 |
FMF | 17 | 15 | 274 | 43 | 349 | 28 | 378 |
MVK | 39 | 15 | 56 | 8 | 118 | 4 | 122 |
PFAPA | 11 | 2 | 99 | 0 | 112 | 158 | 271 |
TRAPS | 7 | 7 | 101 | 5 | 120 | 37 | 158 |
Undefined | 9 | 5 | 57 | 1 | 72 | 63 | 135 |
Others | 0 | 1 | 20 | 2 | 23 | 38 | 60 |
P8 Next generation sequencing-based panel screening in patients with undifferentiated autoinflammatory diseases: friend or foe?
P9 Monogenic diseases masquerading as Behçet’s disease in the young
Charalampia Papadopoulou1, Ebun Omoyinmi1, Ariane Standing1, Jessica Macwilliam2, Clare Pain2, Despina Eleftheriou1,3, Paul Brogan1
1Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; 2Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom; 3 Centre for Adolescent Rheumatology, Arthritis Research UK, London, United Kingdom
Correspondence: Charalampia Papadopoulou
P10 Proteomic profile of patients with different autoinflammatory diseases: an approach to identify new biomarkers
Federica Penco1, Andrea Petretto2, Chiara Lavarello2, Elvira Inglese2, Ilaria Gueli3, Alessia Omenetti3, Martina Finetti3, Federico Tomasi4, Annalisa Barla4, Arinna Bertoni1, Claudia Pastorino1, Marco Gattorno3
1Laboratorio di Immunologia delle Malattie Reumatiche Pediatria II, Università degli Studi di Genova, Genova, Italy; 2Core Facilities, Università degli Studi di Genova, Genova, Italy; 3U.O. Pediatria II, Instituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy; 4Dibris, Università degli Studi di Genova, Genova, Italy
Correspondence: Federica Penco
P11 Through new classification criteria for inherited periodic fevers and PFAPA syndrome: the patient validation phase
Federica Vanoni1,2, Silvia Federici3, Francesca Bovis4, Mariapia Sormani5, Nicola Ruperto3, Marco Gattorno3, Michaël Hofer2 and on behalf of the Expert Committee for the Classification Criteria in periodic fever
1Departement of Pediatric of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland; 2Pediatric Rheumatology Unit, CHUV, Lausanne, Switzerland; 3Pediatria II - Reumatologia, Istituto G. Gaslini, University of Genoa, Genoa, Italy; 4Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy
Correspondence: Federica Vanoni
P12 A preliminary study regarding to the levels of vitamin B12 and folate during colchicine treatment in children with FMF
Özge Kaba1, Mustafa Çakan2, Şerife Gül Karadağ2, Betül Sözeri3, Gonca Keskindemirci1, Nuray Aktay Ayaz2
1Pediatrics, Kanuni Sultan Süleyman Research And Training Hospital, İstanbul, Turkey; 2Pediatric Rheumatology, Kanuni Sultan Süleyman Research And Training Hospital, İstanbul, Turkey; 3Pediatric Rheumatology, Ümraniye Research And Training Hospital, İstanbul, Turkey
Correspondence: Nuray Aktay Ayaz
P13 Longitudinal assessment of iron homeostasis in patients with newly diagnosed familial Mediterranean fever
Özge Kaba1, Nuray Aktay Ayaz2, Şerife Gül Karadağ2, Mustafa Çakan2
1Pediatrics, Kanuni Sultan Süleyman Research and Training Hospital, İstanbul, Turkey; 2Pediatric Rheumatology, Kanuni Sultan Süleyman Research and Training Hospital, İstanbul, Turkey
Correspondence: Nuray Aktay Ayaz
Before treatment | 3th month of treatment | 5th month of treatment | p* | |
---|---|---|---|---|
HGB | 12,11 ± 1,16 (12,08) | 12,20 ± 1,03 (12,05) | 12,38 ± 1,02 (12,31) | 0,027*
|
HCT | 38,05 ± 3,19 (38,02) | 38,63 ± 3,45 (38,30) | 38,82 ± 2,81 (38,27) | 0,135 |
PLT | 350.932 ± 110.096 (334.600) | 310.671 ± 85.475 (309.850) | 303.202 ± 81.570 (296.700) | <0,001*
|
SAA | 192,19 ± 295,14 (38,95) | 20,26 ± 46,58 (3,85) | 9,68 ± 25,81 (3,30) | <0,001*
|
IRON | 53,47 ± 29,56 (50,85) | 66,76 ± 35,61 (56,50) | 67,41 ± 31,15 (64,00) | <0,001*
|
TIBC | 361,09 ± 52,93 (362,50) | 364,78 ± 55,12 (365,00) | 372,91 ± 48,92 (366,00) | 0,163 |
FERRITIN | 56,63 ± 42,46 (45,00) | 34,69 ± 21,34 (30,55) | 32,74 ± 23,80 (25,55) | 0,002*
|
P14 Population based study of frequency of carrying FMF mutation among Armenian females
Artashes Tadevosyan1, Tigran Avagyan1, Gayane Amaryan2,3,4, Hasmik Hayrapetyan5, Anush Budumyan1
1Public Health, YEREVAN STATE MEDICAL UNIVERSITY, Yerevan, Armenia; 2Pediatrics, YEREVAN STATE MEDICAL UNIVERSITY, Yerevan, Armenia; 3National Pediatric Centre for Familial Mediterranean fever, Yerevan, Armenia; 4Arabkir” Joint Medical Centre - Institute of Child and Adolescent Health, Yerevan, Armenia; 5Centre of Medical Genetics - Primary Health Care, Yerevan, Armenia,
Correspondence: Tigran Avagyan
P15 Is routine periodic laboratory work-up necessary for paediatric MEFV (mediterranean fever) carriers
Balahan Balahan, Nesrin Gülez
Behçet Uz Children s Hospital, Izmir, Turkey
Correspondence: Balahan Balahan
P16 Increased psoriasis frequency in patients with familial Mediterranean fever
Ezgi D. Batu1, Abdulsamet Erden2, Emrah Seyhoğlu3, Alper Sarı2, Hafize E. Sönmez1, Berkan Armagan2, Selcan Demir1, Emre Bilgin3, Levent Kılıç2, Ömer Karadağ2, Ali Akdoğan2, Yelda Bilginer1, Ihsan Ertenli2, Sedat Kiraz2, Sule A. Bilgen2, Umut Kalyoncu2, Seza Özen1
1Division of Rheumatology, Department of Pediatrics, HACETTEPE UNIVERSITY FACULTY OF MEDICINE, Ankara, Turkey; 2Division of Rheumatology, Department of Internal Medicine, HACETTEPE UNIVERSITY FACULTY OF MEDICINE, Ankara, Turkey; 3Department of Internal Medicine, HACETTEPE UNIVERSITY FACULTY OF MEDICINE, Ankara, Turkey
Correspondence: Ezgi D. Batu
P17 Periodic fever, aphtous stomatitis, pharyngitis and cervical adentitis (PFAPA) syndrome. A qualitative study of parent's experiences and strategies
Carina Sparud-Lundin1, Stefan Berg2, Anders Fasth3, Anna Karlsson4, Per Wekell5
1Institute of Health and Care Sciences, Sahgrenska Academy, Goteborg, Sweden; 2Pediatric Immunology and Rheumatology, The Queen Silvia Children's Hospital, Goteborg, Sweden; 3Dept of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Goteborg, Sweden; 4Dept of Rheumatology and Inflammation Research, Sahlgrenska Academy, Instutute of Medicine, Goteborg, Sweden; 5NU-Hospital Organisation, Dept of Pediatrics, Uddevalla, Sweden
Correspondence: Stefan Berg
P18 Aicardi-Goutières syndrome with a novel mutation in the SAMHD1 gene
Sorina Boiu1, Adrianos Nezos2, Isabelle Melki3, Argirios Dinopoulos4, Erato Atsali1, Clio Mavragani2, Vana Papaevangelou5, Dimitrios Boumpas6
1Pediatric Rheumatology Unit, Third Department of Pediatrics, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 2Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 3Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR1163, Institut Imagine, Paris, France; 4Pediatric Neurology Unit, Third Department of Pediatrics, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 5Third Department of Pediatrics, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 6Joint Rheumatology Program, Fourth Department of Medicine, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Correspondence: Sorina Boiu
P19 The challenges to diagnose and treat a rare patient with candle syndrome
Martin Boyadzhiev1, Veselin Boyadzhiev1, Lachezar Marinov1, Violeta Iotova1, Sophie Hambleton2, Ivona Aksentijevich3
1Dept. of Pediatrics, Medical University, Varna, Bulgaria; 2Instituste of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom; 3National Human Genome Research Institute, National Institutes of Health, Washington D.C., United States
Correspondence: Martin Boyadzhiev
P20 Complement endorse the pathogenesis in autoinflammation
Juergen Brunner1, Wilfried Posch2, Evelyn Rabensteiner1, Doris Wilflingseder2
1Pediatrics, Medical University Innsbruck, Innsbruck, Austria; 2Division of Hygiene and Medical Microbiology, Medical University Innsbruck, Innsbruck, Austria
Correspondence: Juergen Brunner
P21 Recurrent pericarditis: clinical course and treatment in pediatric patients
Camilla Celani1, Diala Khraiche2, Pierre Quartier3, Damien Bonnet2, Brigitte Bader-Meunier1
1Unité d'Immunologie-Hématologie et Rhumatologie Pédiatriques, Hopital Necker, Paris, France2Cardiologie pediatrique, Hopital Necker, Paris, France3Unitè d'Immunologie-Hématologie et Rhumatologie Pédiatriques, Hopital Necker, Paris, France
Correspondence: Camilla Celani
P22 Sinogenic subdural empyema in two girls treated with Adalimumab for chronic recurrent multifocal osteomyelitis (CRMO)
Anne Estmann Christensen, Peter Toftedal
Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark
Correspondence: Anne Estmann Christensen
P23 Spectrum of chronic recurrent multifocal osteomyelitis in a Belgian cohort of 25 children: clinical presentation, imaging, treatment and outcome
Lien De Somer1, Sara Kaut2, Ine Van den Wyngaert2, Davy Christiaens3, Carine Wouters1, Steven Pans3
1Department of Pediatric Rheumatology, UZ Leuven, Leuven, Belgium; 2Pediatrics, UZ Leuven, Leuven, Belgium; 3Radiology, UZ Leuven, Leuven, Belgium
Correspondence: Lien De Somer
P24 Clinical characteristics of familial Mediterranean fever patients according to their MEFV mutation
Pelin Esmeray1, Zehra S. Arıcı2, Hafize E. Sönmez2, Yelda Bilginer2, Seza Özen2
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; 2Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: Pelin Esmeray
Others (n = 240) | M694V-Homozygote (n = 138) | p | |
---|---|---|---|
Age of diagnosis (years), | 5 (0-17) | 4 (1-15) | 0,098*
|
Disease duration (years), | 6 (0-17) | 7 (1-17) | 0,004*
|
Attack status in last 6 months, n (%) | 72 (30,0) | 65 (47,1) | 0,001**
|
Attacks frequency in last 6 months | 2 (1-19) | 2 (1-15) | 0,722*
|
Disease activity score | 0 (0-5) | 1 (0-6) | <0,001*
|
AIDAI, | 0 (0-14) | 1 (0-9) | <0,001*
|
Regular drug use (n = 192), n (%) | 86 (64,7) | 38 (64,4) | 0,973**
|
Need for addditional treatment (n = 192), n (%) | 7 (5,3) | 13 (22,0) | <0,001**
|
P25 Infection status in children with familial Mediterranean fever (FMF) according to MEFV
Pelin Esmeray1, Ezgi D. Batu2, Zehra S. Arıcı2, Hafize E. Sönmez2, Yelda Bilginer2, Seza Özen2
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; 2Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: Pelin Esmeray
P26 Clinical characteristics of FMF patients according to age groups
Pelin Esmeray1, Ezgi D. Batu2, Hafize E. Sönmez2, Selcan Demir2, Yelda Bilginer2, Seza Özen2
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; 2Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: Pelin Esmeray
Onset age | p | |||
---|---|---|---|---|
≤5 yaş (n = 261) | 6-11 yaş (n = 98) | ≥12 yaş (n = 19) | ||
Age (year), median (min-max) | 10 (2-18) | 13 (7-18) | 17 (14-18) | <0,001*
|
Sex, n (%) Male Girl | 143 (54,8) 118 (45,2) | 56 (57,1) 42 (42,9) | 10 (52,6) 9 (47,4) | 0,897**
|
Attack Status in Last 6 Months n (%) | 100 (38,3) | 29 (29,6) | 8 (42,1) | 0,237**
|
Attack frequency in the last 6 months median (min-max) | 2 (1-19) | 2 (1-6) | 1,5 (1-3) | 0,226*
|
ISSF, median (min-max) | 1 (0-6) | 1 (0-5) | 1 (0-4) | 0,103*
|
Treatment compliance (n = 192), n (%) | 84 (66,7) | 31 (57,4) | 9 (75,0) | 0,363** |
Need for additional treatment (n = 192), n (%) | 12 (9,5) | 7 (13,0) | 1 (8,3) | 0,764** |
P27 Oral findings in children with familial Mediterranean fever
Pelin Esmeray1, Ezgi D. Batu2, Zehra S. Arıcı2, Tülin I. Keçeli3, Yelda Bilginer2, Meryem Tekçiçek3, Seza Özen2
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; 2Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Dentistry, Ankara, Turkey; 3Deparment of Pediatrics Pedodontology, Hacettepe University Faculty of Dentistry, Ankara, Turkey
Correspondence: Pelin Esmeray
All patients (n = 199) | Patients with tooth decay (n = 182) | Patients who did not have tooth decay (n = 17) | |
---|---|---|---|
median (minimum-maximum) | |||
The status of attack at the last six months, n (%) | 115 (57.7) | 75 (97.4) | 2 (2.6) |
The frequency of attacks at the last six months (n = 115) | 0.96 ± 2.08/0 (0-19) | 2 (1-19) | 2.5 (2-3) |
n (%) | |||
Deciduous tooth decay | 166 (83,4) | ||
Permanent tooth decay | 104 (52,3) | ||
Tooth decay | 182 (91,5) | ||
Dental plaque index | 1.26/198 (0-2.25) | ||
Gingival index | 0.87/198 (0-1.81 |
P28 Successful use of tocilizumab, interleukin-6 (IL-6) inhibitor, in a child with TRAPS
P29 The Eurofever project: an update on the longitudinal stage
Martina Finetti, Silvia Federici, Joost Frenkel, Seza Ozen, Helen Lachmann, Fabrizio De Benedetti, Joost Swart, Luca Cantarini, Romina Gallizzi, Marco Cattalini, Rolando Cimaz, Donato Rigante, Jordi Anton, Maria Alessio, Alma Nunzia Olivieri, Pavla Dolezalova, Annette Jansson, Giovanna Fabio, Judith Sanchez Manubens, Eric Hachulla, Rita Consolini, Karoline Krause, Zelal Ekinci, Jurgen Brunner, Isabelle Koné-Paut, Giovanni Filocamo, Maria del Carmen Pinedo, Efimia Papadopoulou-Alataki, Liliana Bezrodnik, Alberto Martini, Nicola Ruperto, Marco Gattorno and on behalf of Eurofever Project
Pediatria II - Reumatologia, Istituto Giannina Gaslini on behalf of Eurofever Project, Genoa, Italy
Correspondence: Martina Finetti
P30 Mevalonate-kinase deficiency in the Czech Republic
P31 Eye manifestations of patients with Muckle-Wells syndrome
sukru cekic1, ozgur yalcinbayır2, Sara Sebnem Kilic1
1Pediatric Rheumatology, Uludag University Medical Faculty, Bursa, Turkey; 2ophthalmatology, Uludag University Medical Faculty, Bursa, Turkey
Correspondence: Sara Sebnem Kilic
P32 Clinical comparison of patients with unifocal and multifocal chronic recurrent multifocal osteomyelitis in an Irish cohort
Daire O'Leary1, Anthony Gerard Wilson2, Emma-Jane MacDermott3, Orla Killeen3
1Paediatric Department, RCSI, Dublin, Ireland; 2School of Medicine, UCD, Dublin, Ireland; 3National Centre for Paediatric Rheumatology, Our Lady's Children's Hospital, Dublin, Ireland
Correspondence: Orla Killeen
Bone in rheumatic diseases
P33 Magnetic resonance imaging bone marrow oedema in children: insight to comprehension and clinical significance
Federico Caldonazzi1, Sara Pieropan2, Maddalena Maschio3, Gloria Dallagiacoma2, Daniela Degani3, Giorgio Piacentini3, Diego A. Ramaroli3, Domenico Biasi2, Maurizio Rossini2
1UOC di Pediatria, Universita' degli Studi di Verona, Verona, Italy; 2UOC di Reumatologia, Università degli Studi di Verona, Verona, Italy; 3UOC di Pediatria, Università degli Studi di Verona, Verona, Italy
Correspondence: Federico Caldonazzi
P34 Performance of bone scan compared to whole body-MRI in evaluation of chronic non-bacterial osteomyelitis
Pei Ling Ooi1, Gemma Buckley2, Lorenzo Biassoni2, Marina Easty2, Sandrine Compeyrot-Lacassagne1
1Department of Rheumatology, Great Ormond Street Hospital for Children, London, United Kingdom;2Department of Radiology, Great Ormond Street Hospital for Children, London, United Kingdom
Correspondence: Pei Ling Ooi
P35 The status of bone metabolism in children with juvenile idiopathic arthritis
Yury M. Spivakovskiy1, Anna Spivakovskaja1, Youri Chernenkov1, Natalya Zacharova2
1Department of Hospitality Pediatrics, SARATOV STATE MEDICAL UNIVERSITY, Saratov, Russian Federation; 2SARATOV STATE MEDICAL UNIVERSITY, Saratov, Russian Federation
Correspondence: Yury M. Spivakovskiy
P36 Tocilizumab (ANTI-IL6R MOAB) achieves complete and sustained remission in a patient with refractory CRMO
Disease outcome
P37 Intraarticular corticosteroid injections (IACI) of temporo-mandibular joints (TMJ) in juvenile idiopathic arthritis (JIA): the patients’ perspective
Alessia Arduini1, Denise Pires-Marafon2, Rebecca Nicolai2, Aurora Pucacco2, Fabrizio De Benedetti2, Silvia Magni-Manzoni2
1Pediatrics, Policlinico Umberto I, “La Sapienza” University, Rome, Italy 2Rheumatology, IRCCS Bambino Gesù Hospital, Rome, Italy
Correspondence: Alessia Arduini
Pre-TMJ IACI | Post-TMJ IACI | p | |
---|---|---|---|
Ability to bite a sandwich/an apple/a “bombolone” | 5,0 (4,8-6,0) | 9,0 (8,0-10,0) | 0,022 |
Ability to eat a pizza or a steak | 5,0 (4,0-7,0) | 9,0 (8,5-10,0) | 0,036 |
Ability to accurately wash the teeth | 4,0 (4,0-7,3) | 10,0 (9,5-10,0) | 0,035 |
TMJ global assessment | 5,0 (3,0-5,3) | 9,0 (8,5-9,5) | 0,022 |
P38 Early pain report in oligoarticular juvenile idiopathic arthritis is related to long-term outcome
Ellen D. Arnstad1,2, Veronika G. Rypdal3,4, Suvi Peltoniemi5, Ellen Nordal3,4, Lillemor Berntson6, Kristiina Aalto5, Anders Fasth7, Troels Herlin8, Susan Nielsen9, Marek Zak9, Pål R. Romundstad10, Marite Rygg2,11 and Nordic Study Group of Pediatric Rheumatology (NoSPeR)
1Department of Pediatrics, Levanger Hospital, Levanger, Norway;2Department of Laboratory Medicine, Children’s and Women’s Health, NTNU - Norwegian University of Science and Technology, Trondheim, Norway;3Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway;4Department of Clinical Medicine, UIT The Arctic University of Norway, Tromsø, Norway;5Department of Pediatrics, Children’s Hospital, Helsinki University Hospital, Helsinki, Finland;6Department of Women`s and Children`s Health, Uppsala University, Uppsala, Sweden;7Department of Pediatrics, University of Gothenburg, Gothenburg, Sweden;8Department of Pediatrics, Århus University Hospital, Århus, Denmark;9Pediatric Rheumatology Department, Pediatric Clinic II, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;10Department of Public Health and General Practice, NTNU - Norwegian University of Science and Technology;11Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway
Correspondence: Ellen D. Arnstad
P39 HLA II class alleles in juvenile idiopathic arthritis patients with and without chronic arthritis signs in temporomandibular joints evaluated with contrast enhanced MRI
Zane Davidsone1,2, Elena Eglite3, Aleksandrs Kolesovs4, Ruta Santere1, Valda Stanevica1
1Rheumatology, Childrens university hospital, Riga, Latvia; 2Pediatric, Riga`s Stradins University, Riga, Latvia; 3Laboratory of clinical immunology and immunogenetics, Riga Stradins University, Riga, Latvia; 4University of Latvia, Riga, Latvia
Correspondence: Zane Davidsone
P40 The role of antinuclear antibodies positivity in predicting clinical remission in juvenile idiopathic arthritis
Raquel M. Ferreira, Francisca Aguiar, Mariana Rodrigues, Iva Brito
São João Hospital Centre, Porto, Portugal
Correspondence: Raquel M. Ferreira
P41 Evaluation of knee joint Q angle and balance in juvenile idiopathic arthritis patients with pesplanovalgus deformity
Eylul Pinar Kisa1, Serap Inal2, Ela Tarakci3, Nilay Arman3, Ozgur Kasapcopur4
1Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Yeditepe University, Istanbul, Turkey; 2Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Bahcesehir University, Istanbul, Turkey; 3Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Istanbul, Turkey 4Department of Pediatric Rheumatology, Medical Faculty of Cerrahpasa, Istanbul University, Istanbul, Turkey
Correspondence: Eylul Pinar Kisa
P42 Development of a unique platform for pediatric immuno-rheumatologic diseases (JIRCOHORTE): inclusion of 3266 patients.
M. Mejbri1, R. Carlomagno1, F. Hofer1, V. Hentgen2, B. Bader-Meunier3, B. Fonjallaz4, S. Georgin- Lavialle5, Y. Guex-Crosier6, P. Scolozzi7, A. Woerner8, E. Cannizzaro9, D. Kaiser10, G. Berthet11, W. Baer12, F. Vanoni1, K Theodoropoulou1, A. Belot13, M. Hofer1
1Consultation Romande d’immuno-rhumatologie pediatrique CHUV, HUG, Lausanne, Geneva, Switzerland, 2Centre Hospitalier de Versailles, Versailles, France 3Hôpital Universitaire Necker, Paris, France, 4Ligue Genevoise contre le Rhumatisme, Geneva, Switzerland, 5Hôpital Tenon, Paris, France, 6Hôpital Ophtalmique Jules-Gonin, Lausanne, Switzerland 7HUG, Geneva, Switzerland 8Kinderspital Beider, Basel, Switzerland 9Kinderspital, Zürich, Switzerland 10Kinderklinik, LUCERNE, Switzerland 11Kinderklinik, Aarau, Switzerland 12Kantonspital, Graubunden, Switzerland, 13Hôpital Femme Mère Enfant, Lyon, France
Correspondence: M. Mejbri
Genetics and environment
P43 Progressive pseudorheumatoid dysplasia resolved by whole exome sequencing: a novel mutation in WISP3 and review of the literature
Aviva Eliyahu1,2, ben pode-shakked3,4,5, Asaf Vivante5,6, Ortal Barel7, Shai Padeh8,9, Dina Marel-Yagel9,10, Alvit Veber11, Shachar Abudi12, Irit Tirosh2,13, Shiri Shpilman2,14, Shirlee Shril15, gideon rechavi7,16,17, Friedhelm Hildebrandt18, Mordechai Shohat7,19, yair anikster3,20,21
1 Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, tel hashomer, Israel; 2Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel; 3Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel; 4Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel; 5The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer, Israel; 6Division of Nephrology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States; 7Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel; 8Pediatric Rheumatology Unit and Department of Pediatrics, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; 9Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 10Metabolic Disease Unit Israel, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; 11Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; 12Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; 13Pediatric Rheumatology Unit and Department of Pediatrics, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel; 14Pediatric Rheumatology Unit and Department of Pediatrics, Edmond and Lily Safra Children's Hospital, Tel Hashomer, Israel; 15Division of Nephrology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States; 16Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 17The Wohl Institute for Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel; 18 Division of Nephrology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston MA, United States; 19Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 20Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 21The Wohl Institute for Translational Medicine, Sheba Medical Center, Tel-Hashomer, Israel
Correspondence: Aviva Eliyahu
P44 Cytokines genes and the severity of juvenile idiopathic arthritis
Liliia S. Nazarova1, Kseniia V. Danilko1, Tatiana V. Viktorova1,2, Viktor A. Malievsky1
1Bashkir State Medical University, Ufa, Russian Federation; 2Institute of Biochemistry and Genetics, Ufa, Russian Federation
Correspondence: Viktor A. Malievsky
P45 Single nucleotide polymorphisms in survivin gene are associated to response to methotrexate in juvenile idiopathic arthritis
Mojca Zajc Avramovič1, Vita Dolzan2, Natasa Toplak1, Tadej Avcin1
1Department of Allergology, Rheumatology and Clinical Immunology, Children’s Hospital, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia 2Institute of Biochemistry, Medical faculty, Ljubljana, Slovenia
Correspondence: Mojca Zajc Avramovič
Imaging - Vasculitides
P46 Henoch schonlein purpura nephitis: initial risk factor and outcomes in a tertiary center of Latin America
Izabel M. Buscatti, Beatriz B. Casella, Nadia E. Aikawa, Andrea Watanabe, Sylvia C. Fahrat, Lucia M. Campos, Clovis A. Silva
Pediatric Rheumatology Division, CHILDREN’S INSTITUTE, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, São Paulo, Brazil
Correspondence: Izabel M. Buscatti
P47 Toward the development of a new radiographic score for diagnosis and monitoring of temporomandibular joint disease in children with juvenile idiopathic arthritis
Gabriella Giancane, Giacomo Chiappe, Fiammetta Sertorio, Veronica Incarbone, Alessandro Consolaro, Nicola Laffi, Gian Michele Magnano, Angelo Ravelli
Istituto Giannina Gaslini, Genoa, Italy
Correspondence: Gabriella Giancane
TMJ ACTIVITY PARAMETERS | |||
---|---|---|---|
Right | Left | Total score | |
Joint effusion | YES □ NO □ | YES □ NO □ | 0-2 |
Contrast enhancement (CE) | YES □ NO □ | YES □ NO □ | 0-2 |
Bone edema/bone marrow CE | YES □ NO □ | YES □ NO □ | 0-2 |
Total activity score | 0-3 | 0-3 | 0-6 |
TMJ DAMAGE PARAMETERS | |||
Erosions/irregularities of the condyle | YES □ NO □ | YES □ NO □ | 0-2 |
Disc abnormalities | YES □ NO □ | YES □ NO □ | 0-2 |
Flattening of condyle | MODERATE/SEVERE □ MILD□ NO□ | MODERATE/SEVERE □ MILD□ NO□ | 0-4 |
Mandibular asimmetry | YES □ NO □ IF YES: RIGHT < □ LEFT < □ | 0-1 | |
Total damage score | 0-5 | 0-9 |
P48 Determining disease activity in CIA by optical imaging of phagocyte migration
Sandra Gran1, Lisa Honold2, Olesja Fehler1, Stefanie Zenker1, Sven Hermann2, Michael Schäfers2, Thomas Vogl1, Johannes Roth1
1Institute of Immunology, Münster, Germany; 2European Institute for Molecular Imaging, Münster, Germany
Correspondence: Sandra Gran
P49 Juvenile Sjögrens syndrome (JSS): comparing glandular ultrasound in primary and secondary JSS
Johannes-Peter Haas, Manuela Krumrey-Langkammerer
German Center for pediatric and adolescent rheumatology, Garmisch-Partenkirchen, Germany
Correspondence: Manuela Krumrey-Langkammerer
pjSS (n = 9) | sjSS other (n = 8) | sjSS in MCTD (n = 8) | All (n = 25) | |
---|---|---|---|---|
Decrease in echogenity | 3 (33,3%) | 3 (37,5%) | 2 (25%) | 18 (72%) |
Inhomogenous parenchyma | 9 (100%) | 7 (87,5%) | 6 (75%) | 22 (88%) |
Hypoechoic areas | 9 (100%) | 8 (100%) | 7 (87,5%) | 24 (96%) |
Hyperechoic reflexes | 7 (77,7%) | 6 (75%) | 6 (75%) | 19 (76%) |
Disturbed border | 4 (44,4%) | 2 (25%) | 0 | 6 (24%) |
P50 Toward the achievement of an agreement between clinical and ultrasound assessment of the ankle region
Stefano Lanni1, Alessandra Alongi1, Adele Civino2, Alessandro Consolaro1,3, Giovanni Filocamo4, Angelo Ravelli1,3
1IRCCS Istituto Giannina Gaslini, Genova, Italy; 2Pia Fondazione di Culto e Religione Card. G. Panico, Tricase, Italy; 3Università degli Studi di Genova, Genova, Italy; 4Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
Correspondence: Stefano Lanni
P51 Kawasaki disease: initial echocardiogram predicts subsequent coronary disease and immunoglobuline resistance
Dima Chbeir1, Jean Gaschinard1, Ronan Bonnefoy1, Constance Beyler2, Isabelle Melki1, Albert Faye1, Ulrich Meinzer 1
1Pédiatrie générale, maladies infectieuses et médecine interne, Paris, France 2Service de cardiologie pédiatrique, Hôpital Robert Debré, Paris, France
Correspondence: Ulrich Meinzer
P52 Childhood-onset Takayasu arteritis: a referral center experience in Turkey
Sezgin Sahin1, Duhan Hopurcuoglu1, Sule Bektas1, Ezgi Belhan1, Amra Adrovic1, Kenan Barut1, Nur Canpolat2, Salim Calıskan2, Lale Sever2, Ozgur Kasapcopur1
1Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey 2Pediatric Nephrology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
Correspondence: Sezgin Sahin
P53 Low dose CT coronary angiography and calcium scoring in patients with Kawasaki disease in convalescent phase- a preliminary study
Rajkumar Chakraborty1, Surjit Singh2, Manphool Singhal1, Deepti Suri2
1Radiodiagnosis and Imaging, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India; 2Allergy immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India
Correspondence: Surjit Singh
P54 Low dose dual source CT coronary angiography and calcium scoring in children with Kawasaki disease not treated with intravenous immunoglobulin– a preliminary study
Santosh Dusad1, Surjit Singh1, Manphool Singhal2, Deepti Suri1
1Allergy immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India 2Radiodiagnosis and Imaging, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India
Correspondence: Surjit Singh
P55 Flow mediated dilatation of brachial artery during the acute and convalescent stages of Kawasaki disease-a preliminary study
Santosh Kumar1, Surjit Singh1, Manphool Singhal2, Vivek Kumar3, Deepti Suri1
1Allergy immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2Radiodiagnosis and Imaging, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 3Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India,
Correspondence: Surjit Singh
P56 Discrepancies between clinical assessment and MR imaging in JIA
E. Charlotte van Gulik1, Robert Hemke1, Mendy M. Welsink-Karssies2, Dieneke Schonenberg1, Koert M. Dolman3, Anouk M. Barendregt1, Charlotte M. Nusman1, Taco W. Kuijpers1, Mario Maas1, J. Merlijn van den Berg1
1AMC, Amsterdam, Netherlands; 2OLVG, Amsterdam, Netherlands; 3Reade, Amsterdam, Netherlands
Correspondence: E. Charlotte van Gulik
Clinically Active | Clinically Inactive | |||||
---|---|---|---|---|---|---|
Variable | Concordant n = 47 | Discordant n = 25 | p-value | Concordant n = 34 | Discordant n = 18 | p-value |
Female gender, n(%) | 26 (55.3) | 18 (72.0) | 0.209 | 23 (44.2) | 10 (19.2) | 0.389 |
Age, years | 10.9 (8.6-13.7) | 13.2 (11.3-15.6) | 0.006 | 14.4 (12.1-16.3) | 10.7 (9.3-13.6) | 0.008 |
Oligoarticular JIA, n(%) | 21 (44.7) | 2 (8.0) | 0.001 | 11 (32.4) | 11 (61.1) | 0.076 |
Polyarticular JIA, n(%) | 16 (34.0) | 18 (72.0) | 0.003 | 19 (55.9) | 4 (22.2) | 0.038 |
Other subtypes, n(%) | 10 (21.3) | 5 (20) | 1.000 | 4 (11.8) | 3 (16.7) | 0.682 |
P57 Flow cytometry based assay of platelet reactivity in children with Kawasaki disease- a preliminary study
Pandiarajan Vignesh1, Surjit Singh1, Amit Rawat1, Man Updesh S. Sachdeva2, Jasmina Ahluwalia2
1ALLERGY IMMUNOLOGY UNIT, PEDIATRICS, POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, Chandigarh, India; 2Hematology, POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, Chandigarh, India
Correspondence: Pandiarajan Vignesh
S no | Category | Median MPA% (IQR) | P value |
---|---|---|---|
1 | At enrolment (n = 14) | 41.31 (26.6, 52.69) | <0.001* |
2 | 24 hours after IVIg (n = 14) | 18.55 (9.2, 22.99) | |
3 | Follow-up at 3rd month (n = 11) | 7.55 (4.15, 14.6) |
Immunodeficiency and infection related arthritis
P58 Deficiency of CD70 is responsible of a case of chronic active EBV (CAEBV) infection presenting as periodic fever
Roberta Caorsi1, Marta Rusmini2, Stefano Volpi1, Sabrina Chiesa1, Caludia Pastorino1, Francesca Minoia1, Alice Grossi2, Sara Signa1,3, Paolo Picco1, Angelo Ravelli1,3, Isabella Ceccherini2, Marco Gattorno1
1Second division of Pediatrics, G. Gaslini Institute, Genova, Italy; 2Division of Human Genetics, G. Gaslini Institute, Genova, Italy’; 3DINOMGI, University of Genova, Genova, Italy
Correspondence: Roberta Caorsi
P59 Clostridium difficile enterocolitis and reactive arthritis: a case report ad re-view of the literature
Lorenzo Mambelli1, Michela Cappella2, Martina Mainetti1, Federico Marchetti1
1Pediatrics, S. Maria delle Croci Hospital, Ravenna, Italy; 2Pediatric and Adolescence Rheumatology, S.Maria Nuova Hospital, Reggio Emilia, Italy
Correspondence: Lorenzo Mambelli
Juvenile idiopathic arthritis (JIA) in practice
P60 The effect of task-oriented training with video-based games on activity performance and participation in children with juvenile idiopathic arthritis
Nilay Arman1, Ela Tarakci1, Devrim Tarakci2, Ozgur Kasapcopur3
1Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Istanbul University, Istanbul, Turkey; 2Division of Ergotherapy, Istanbul Medipol University, Istanbul, Turkey; 3Department of Pediatric Rheumatology, Medical Faculty of Cerrahpasa, Istanbul University, Istanbul, Turkey
Correspondence: Nilay Arman
P61 Analysis of activity performance problems in patients with juvenile idiopathic arthritis
Nilay Arman1, Ela Tarakci1, Ozgur Kasapcopur2
1Faculty of Health Sciences, Division of Physiotherapy and Rehabilitation, Medical Faculty of Cerrahpasa, Istanbul University, Istanbul, Turkey; 2Department of Pediatric Rheumatology, Medical Faculty of Cerrahpasa, Istanbul University, Istanbul, Turkey
Correspondence: Nilay Arman
Activity | % | Activity | % | Activity | % | Activity | % |
---|---|---|---|---|---|---|---|
Carrying something | 66 | Using a knife | 20 | Drinking | 8 | Gripping small objects | 4 |
Writing | 50 | Buttoning | 18 | Cutting nail | 8 | Using a scissors | 4 |
Opening a bottle cap | 48 | Taking a bath | 16 | Washing dishes | 6 | Stirring a soup | 2 |
Dressing | 38 | Peeling a fruit | 14 | Pushing something | 6 | Opening a zipper | 2 |
Opening a door with handle/knob | 38 | Washing hair | 14 | Removing a sock | 4 | Acclaiming | 2 |
Combing | 28 | Tying a shoelace | 12 | Reaching to grab something | 4 | Using a fork | 2 |
Unlocking | 28 | Brushing teeth | 10 | Unpacking | 4 | ||
Tapping | 26 | Eating | 10 |
P62 Vaccination coverage in children with rheumatic diseases
Maša Bizjak1, Tadej Avčin1,2, Nataša Toplak1,2
1Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Correspondence: Maša Bizjak
P63 Quality of referral letters to pediatric rheumatology and its impact on access to care
P64 Contextualizing guidelines for the management of juvenile idiopathic arthritis in developing countries: a needs assessment
Mercedes O. Chan1, Ricardo Russo2, Lawrence Okong'o3, Christiaan Scott4
1Pediatrics (Rheumatology), University of Alberta, Edmonton, Canada; 2Immunology and Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina; 3Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya, 4University of Cape Town, Cape Town, South Africa
Correspondence: Mercedes O. Chan
P65 Evaluation of the diagnostic delay and access to remission in JIA patients of the JIR cohorte
Caroline Freychet1, Natalia Cabrera2, Lega Jean Christophe2, Michael Hofer3, Alexandre Belot4 and JIR cohorte
1Laboratory HESPER (Health Services and Performance Research), University Claude Bernard Lyon 1, Lyon, France; 2Team Evaluation et Modélisations des Effets Thérapeutiques, University Claude Bernard Lyon 1, Lyon, France; 3Paediatric Rheumatology, University hospital of Lausanne, Lausanne, Switzerland; 4Paediatric Rheumatology, University hospital of Lyon, Lyon, France
Correspondence: Caroline Freychet
P66 Performance of disease activity measures in pediatric patients with enthesitis-related arthritis
P67 Teaching adult rheumatology fellows to help young adult patients ‘stick the landing’ when transferring from pediatric to adult rheumatology care
Rebecca E. Sadun1, Gary R. Maslow2, Lisa G. Criscione-Schreiber3
1Internal Medicine and Pediatrics, Duke University, Durham, NC, United States; 2Pediatrics and Psychiatry, Duke University, Durham, NC, United States; 3Internal Medicine, Duke University, Durham, NC, United States
Correspondence: Rebecca E. Sadun
Skill 1 | Skill 2 | Skill 3 | Skill 4 | Skill 5 | Total/Avg | Skill 6 | |
---|---|---|---|---|---|---|---|
Pre-workshop (n = 12) | 3.5 | 4.3 | 3.8 | 2.8 | 2.3 | 16.7/3.3 | 3.5 |
Post-workshop (n = 7) | 4.6 | 5.0 | 4.4 | 4.7 | 2.6 | 21.3/4.3 | 2.0 |
p-value | <0.01 | <0.05 | 0.18 | 0.01 | 0.86 | 0.01 | 0.01 |
P68 No radiographic damage after early aggressive treatment in juvenile idiopathic arthritis
Dieuwke Schreurs1,2, Willemieke van Braak2, Petra Hissink Muller1, Charlotte Nusman2
1Pediatric Rheumatology, LUMC, Leiden, Netherlands; 2Radiology, AMC, Amsterdam, Netherlands
Correspondence: Dieuwke Schreurs
P69 The characteristic of the undifferentiated arthritis in juvenile idiopathic arthritis
Betul Sozeri1, Eylem Topaktas1, Duygu Kurtulus2
1Pediatric Rheumatology, University of Health Sciences, Istanbul, Umraniye Training and Research Hospital, Istanbul, Turkey; 2Physical Medicine and Rehabilitation, University of Health Sciences, Istanbul, Umraniye Training and Research Hospital, Istanbul, Turkey
Correspondence: Betul Sozeri
Juvenile idiopathic arthritis
P70 Time of onset of ocular disease in 336 children with juvenile idiopathic arthritis-associated uveitis: evidence-based data to refine current ophthalmologic screening guidelines
Serena Calandra1, Valentina Muratore2, Valentina Ravaschio1, Gabriella Giancane1, Alessandra Alongi1, Angela Pistorio1, Alessandro Consolaro1, Angelo Ravelli1
1Istituto Giannina Gaslini, Genova, Italy; 2Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Correspondence: Serena Calandra
Follow-up (years) | 0 to 1 | 1 to 2 | 2 to 4 | 4 to 6 | 6 to 8 | 8 to 9 | > 9 |
---|---|---|---|---|---|---|---|
N. | 160 | 66 | 51 | 31 | 15 | 6 | 7 |
Cumulative % | 47.6 | 67.3 | 82.4 | 91.7 | 96.1 | 97.9 | 100 |
P71 An open-label extension study to assess the long-term safety and clinical benefit of etanercept in pediatric patients with extended oligo, enthesitis related, and psoriatic JIA: 6-year data from the clipper studies
Ivan Foeldvari1, Tamas Constantin1, Jelena Vojinovic1, Gerd Horneff1, Joke Dehoorne1, Gordana Susic1, Katarzyna Kobusinska1, Violeta Panaviene1, Zbigniew Zuber1, Valda Stanevica1, Vyacheslav Chasnyk1, Ronald Pedersen2, Jack Bukowski2, Tina Hinnershitz2, Bonnie Vlahos2, Alberto Martini1, Nicolino Ruperto1 on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO)
1PRINTO, Genoa, Italy; 2Pfizer, Collegeville, PA, United States
Correspondence: Ivan Foeldvari
Clinical Outcomes Mean (95% CI) | Safety Summary (to m72) N (EP100PY) unless otherwise stated | ||||||||
---|---|---|---|---|---|---|---|---|---|
BL1(n = 127) | m241(n = 109) | m482(n = 64) | m722(n = 47) | eoJIAEXP = 245.607 PY | ERAEXP = 158.888 PY | PsAEXP = 119.945 PY | TotalEXP = 524.441 PY | ||
PtGA | 4.96 (4.6,5.4) | 0.97 (0.7,1.2) | 1.32 (0.9,1.8) | 1.29 (0.9,1.7) | TEAEs* | 244 (99.35) | 151 (95.04) | 90 (75.03) | 485 (92.48) |
PGA | 5.02 (4.7,5.3) | n = 108 0.62 (0.5,0.8) | n = 63 0.67 (0.5,0.9) | 0.76 (0.5,1.0) | TE infections | 351 (142.91) | 93 (58.53) | 117 (97.54) | 561 (106.97) |
CRP, mg/L | 8.26 (5.7,10.8) | n = 103 2.76 (1.7,3.8) | 2.85 (1.6,4.1) | n = 46 1.58 (1.2,2.0) | TEAEs* causing withdrawal, n (%) | 5 (2.04) | 8 (5.03) | 0 | 13 (2.48) |
JADAS 73 joints | n = 119 17.16 (15.9,18.4) | n = 102 2.28 (1.7,2.9) | n = 61 2.48 (1.8,3.1) | n = 29 3.12 (2.2,4.1) | TE infections causing withdrawal, n (%) | 2 (0.81) | 0 | 1 (0.83) | 3 (0.57) |
No. active joints | 6.74 (5.9,7.6) | 0.61 (0.2,1.0) | n = 63 0.49 (0.3,0.7) | n = 30 0.60 (0.2,1.0) | Serious TEAEs | 11 (4.48) | 17 (10.70) | 4 (3.33) | 32 (6.10) |
No. active joints (LOM) | 5.72 (5.0,6.5) | 1.06 (0.5,1.6) | n = 63 1.02 (0.6,1.4) | n = 30 1.10 (0.5,1.8) | Serious TE infections | 5 (2.04) | 4 (2.52) | 4 (3.33) | 13 (2.48) |
Opportunistic infections†
| 0 | 1 (0.63) | 1 (0.83) | 2 (0.38) |
P72 Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing (EMDR)
Lea Höfel1, Bruno Eppler1, Elisabeth Schnöbel-Müller1, Johannes-Peter Haas2, Boris Hügle2
1Psychology, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany; 2Rheumatology, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
Correspondence: Lea Höfel
P73 The comparison characteristic between patients with systemic onset of juvenile idiopathic arthritis with and without lung involvement.
Mikhail M. Kostik1, Eugenia Isupova1, Irina Chikova1, Margarita Dubko1, Vera Masalova1, Ludmila Snegireva1, Olga Kopchak1,2, Tatyana Kornishina1, Natalia Abramova1, Maria Rumyantseva1, Daria Dzhilkaidarova1, Maria Kaneva1, Olga Kalashnikova1, Vyacheslav Chasnyk1
1Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation; 2Kirov’s regional children’s hospital, Kirov, Russian Federation
Correspondence: Mikhail M. Kostik
Parameter | ALI (n = 18) | W\o ALI (n = 67) | p |
---|---|---|---|
Hemoglobin, g/l | 86,5 (80,0; 108,0) | 105,0 (94,0; 116,0) | 0,003 |
Platelets, x109/l | 201,0 (95,0; 492,0) | 454,0 (361,0; 588,0) | 0,006 |
CRP, mg/l | 104,8 (37,5; 154,0) | 47 (18,0; 104,0) | 0,07 |
LDH, U/l | 1042,0 (543,0; 1230,0) | 516,0 (395,0; 676,0) | 0,012 |
Ferritin, ng/ml | 1759,0 (1144,0; 11300,0) | 321,0 (139,0; 1278,0) | 0,0009 |
Prothrombin, % | 71,1 (63,0; 79,0) | 91,0 (79,0; 98,0) | 0,0009 |
Fibrinogen, g/l | 1,8 (0,8; 4,0) | 4,7 (3,2; 5,7) | 0,012 |
Total protein, g/l | 64,6 (55,0; 70,3) | 71,2 (67,0; 77,0) | 0,002 |
Albumin, % | 24,1 (23,0; 25,6) | 39,0 (31,8; 43,2) | 0,00001 |
P74 Decreasing prevalence of uveitis in children with juvenile idiopathic arthritis seen over a 30-year period
Valentina Ravaschio1, Valentina Muratore2, Serena Calandra1, Gabriella Giancane1, Alessandra Alongi1, Angela Pistorio1, Alessandro Consolaro1, Benedetta Schiappapietra1, Angelo Ravelli1
1Istituto Giannina Gaslini, Genova, Italy; 2Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Correspondence: Valentina Ravaschio
Before 1997 (n = 211) | 1997-2005 (n = 602) | After 2005 (n = 612) | |
---|---|---|---|
number of Uveitis | 60 (28,4%) | 149 (24,8%) | 127 (20,8%) |
Age at onset <3 | 96 (45,5%) | 273 (45,3%) | 302 (49,3%) |
Age at onset 3-7 | 80 (37,9%) | 203 (33,7%) | 169 (27,6%) |
Age at onset >7 | 35 (16,6%) | 126 (20,9) | 141 (23,0%) |
Extended oligoarthritis | 35 (16,6%) | 84 (14,0%) | 97 (15,8%) |
Persistent oligoarthritis | 117 (55,5%) | 317 (52,7%) | 348 (56,9%) |
FR-negative poliarthritis | 35 (16,6%) | 139 (23,1%) | 138 (22,5%) |
Psoriatic arthritis | 11 (5,2%) | 21 (3,5%) | 10 (1,6%) |
Undifferentiated arthritis | 13 (6,2%) | 41 (6,8%) | 19 (3,1%) |
P75 Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy
Hafize E. Sönmez, Ezgi D. Batu, Selcan Demir, Yelda Bilginer, Seza Özen
Department of Pediatrics, Division of Rheumatology, HACETTEPE UNIVERSITY FACULTY OF MEDICINE, Ankara, Turkey
Correspondence: Hafize E. Sönmez
P76 Epidemiology, clinical manifestations and treatment of systemic-onset juvenile idiopathic arthritis (SOJIA): a multicentric study through the international platform JIRcohorte.
Katerina Theodoropoulou1, Alexandre Belot2, Véronique Hentgen3, Isabelle Kone-Paut4, Carine Wouters5, Kenza Bouayed6, Elvira Cannizzaro7, Aurélia Carbasse8, Etienne Merlin9, Claire Ballot10, Daniela Kaiser11, Pascal Pillet, Andreas Woerner 13, Walter Bär14, Sylvaine Poignant15, Véronique Despert16, Caroline Freychet17, Gerald Berthet18, Laetitia Higel19, Tu Tran20, Federica Vanoni21, Sophie Georgin-Lavialle22, Michaël Hofer1
1Pediatric Rheumatology, CHUV, Lausanne, Switzerland; 2Hospices Civils de Lyon, Lyon, France; 3CH de Versailles - Hôpital André Mignot, Paris, France; 4Centre Hospitalier Universitaire Kremlin-Bicêtre, Paris, France ; 5UZ Leuven, Leuven, Netherlands ; 6Hôpital d’Enfants Ebnou Rochd Casablanca, Casablanca, Morocco; 7Kinderspital Zürich, Zürich, Switzerland; 8CHU Arnaud de Villeneuve Montpellier, Montpelier, France; 9Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France; 10CHRU Besançon, Besançon, France; 11Luzerner Kantonspital, Lucerne, Switzerland; 12CHU de Bordeaux, Bordeaux, France; 13Universitäts-Kinderspital beider Basel, Basel, Switzerland; 14Kantonspital Graubünden, Graubünden, Switzerland; 15CHU Nantes, Nantes, France; 16CHU Rennes, Rennes, France; 17CHU St-Etienne, St-Etienne, France; 18Kantonspital Aarau, Aarau, Switzerland; 19Hôpital Hautepierre Strasbourg, Strasbourg, France; 20CHU Nîmes, Nîmes, France; 21L’Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland; 22Hôpital TENON, Paris, France
Correspondence: Katerina Theodoropoulou
P77 Autoinflammatory mechanisms via NF-KB and caspase-1/IL-1 inflammasome pathways in ana negative juvenile idiopathic arthritis
Andrea Zacarias1, Anna Mensa2, Estibaliz Iglesias1, Rosa Bou1, Joan Calzada1, Jordi Anton1, Juan Ignacio arostegui2, Juan Manuel Mosquera1, Violeta Bittermann1
1Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain; 2Inmunology, Hospital Clinic, Barcelona, Spain
Correspondence: Andrea Zacarias
Genes | MEFV | MEFV | MEFV | TNFRSF1A | NLRP3 | NOD2 | NOD2 | NOD2 | PSTPIP1 |
---|---|---|---|---|---|---|---|---|---|
Mutation | E148Q | I591T | M694I | P46L | V198M | D925G | N289S | E778K | G258a |
JIA Patients | 7/101 6,9% | 4/101 3,9% | 3/101 2,9% | 1/101 0,9% | 4/101 3,9% | 1/101 0,9% | 4/101 3,9% | 1/101 0,9% | 1/101 0,9% |
Iberian Population | 0/107 0% | 2/107 1,8% | 18/69.706 0,03% | 0/107 0% | 1/107 1,8% | 1/107 1,8% | 1/107 1,8% | 0/107 0% | 1/6498 0,01% |
Juvenile idiopathic arthritis (JIA) (oligo, poly, psoriatic)
P78 The lull before the TMJ storm: identifying a window of opportunity for early identification of TMJ arthropathy
Clare Marie Adams1, Clarissa Pilkington2
1Rheumatology, Great Ormond Street Hospital for Children, London, United Kingdom; 2Consultant Paediatric Rheumatologist, Great Ormond Street Hospital, London, United Kingdom
Correspondence: Clare Marie Adams
P79 Burden of disease in the pediatric rheumatology clinic at Alain Hospital: the UAE experience
Amal A. Alhosani
child health institute, Alain Hospital, alain, abu dhabi, United Arab Emirates
P80 Investigating longitudinal course of ankle involvement in relation to treatment in children with JIA using a multistate markov model approach
Alessandra Alongi1,2, Alessandro Consolaro2, Angelo Ravelli2
1Università degli Studi di Genova; 2Instituto Giannina Gaslini, Genova, Italy
Correspondence: Alessandra Alongi
P81 Novel mutations in PRG4 gene in one Greek family with camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome
Sorina Boiu1, Mouna Barat2, Isabelle Touitou3, David Geneviève4, Vasileios Kontogeorgakos5, Erato Atsali6, Dimitrios Boumpas7, Vana Papaevangelou8
1Pediatric Rheumatology Unit, Third Department of Pediatrics, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece, 2Laboratoire de Génétique, Hôpital Arnaud de Villeneuve, CHRU Montpellier Montpellier, France, 3Laboratoire de Génétique, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France 4Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Unité Inserm U1183, CHU Montpellier, Université Montpellier, Montpellier, France, 5First Department of Orthopedics, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece 6Pediatric Rheumatology Unit, Third Department of Pediatrics, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece 7Joint Rheumatology Program, Fourth Department of Medicine, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece 8Third Department of Pediatrics, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Correspondence: Sorina Boiu
P82 Dental anxiety and oral health in juvenile idiopathic arthritis
Christina Boros1, Jason Armfiled2
1Discipline of Paediatrics, University of Adelaide, Adelaide, Australia; 2Australian Research Centre for Population Oral Health, University of Adelaide, Adelaide, Australia
Correspondence: Christina Boros
P83 Characterization of a Colombian cohort with juvenile idiopathic arthritis: a single multicenter experience
Miguel Cañola1, Maria A. Alzate2, Deicy Hernandez-Parra2, Diana Echeverry2, Juan C. Uribe-Salazar3, Javier Alvarez4, Lorena Londoño1, Paula Ortiz-Salazar2, Ricardo Pineda2
1Rheumatology division, Artmedica, IPS, Medellin, Colombia; 2Clinical information group, Artmedica, IPS, Medellin, Colombia; 3School of Statistics, Faculty of Sciences, National University of Colombia, Medellin, Colombia; 4Medical student, Universidad CES, Medellin, Colombia
Correspondence: Miguel Cañola
All N = 342 | Oligoarthritis N = 91 | Polyarthritis N = 120 | Systemic N = 28 | Enthesitis related – Psoriatic N = 83 | Un classified N = 20 | p-value | |
---|---|---|---|---|---|---|---|
Age at onset (median) | 7 | 8 | 10 | 6 | 10 | 9 | <.0001 |
Duration of disease (median) | 4 | 3 | 7 | 6,5 | 3 | 33 | <.0001 |
Gender Male:Female | 4:6 | 4:6 | 2:8 | 4:6 | 7:3 | 4:6 | <.0001 |
N % | N % | N % | N % | N % | N % | p-value | |
RF (+) | 92/252 36,5 | 17/63 26,9 | 62/112 55,3 | 3/15 20 | 5/50 10 | 5/12 41,6 | <.0001 |
HLA-B27 | 26/126 20,6 | 7/34 20,5 | 3/23 13,1 | 0/4 0 | 15/61 24,6 | 1/4 25 | 0,648 |
Bone erosions | 33/147 22,4 | 4/38 10,5 | 17/66 25,7 | 4/7 57 | 2/27 7,4 | 6/9 66,6 | 0.0002 |
Axial involvement | 60 17,5 | 10 10,9 | 14 11,6 | 4 14,2 | 30 36,4 | 2 10 | <.0001 |
Peripheral involvement | 285 83,3 | 80 87,9 | 103 85,8 | 22 78,5 | 72 86,7 | 8 40 | <.0001 |
P84 Effectiveness and safety of tocilizumab in juvenile idiopathic arthritis (JIA) in clinical practice.
Gisela Díaz-Cordovés1,2, Natalia Mena1, Esmeralda Nuñez-Cuadros2, Sara Manrique1, Rocio Galindo-Zavala2
1Department of Rheumatology, at the University Regional Hospital of Malaga (HRUM), MÁLAGA, Spain; 2Pediatric Rheumatology Unit, at the University Regional Hospital of Malaga (HRUM), MÁLAGA, Spain
Correspondence: Gisela Díaz-Cordovés
P85 Fat mass in juvenile idiopathic arthritis. Should we think about it?
Gisela Díaz-Cordovés1,2, Esmeralda Nuñez-Cuadros1, Rocio Galindo-Zavala1, Sara Manrique2, Mena Natalia2
1PEDIATRIC RHEUMATOLOGY UNIT, HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA, MÁLAGA, Spain; 2Rheumatology D., HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA, MÁLAGA, Spain
Correspondence: Gisela Díaz-Cordovés
VARIABLE | n = 80 |
---|---|
Age in years, median (±DE) | 10,7 (3,3) |
Sex, female; n (%) | 56 (70) |
BMI | |
Median en kg/m2 (±DE) | 18,2 (4,2) |
Percentile, median (±DE) | 42,0 (29,9) |
Index waist/hip (±DE) | 0,84 (0,06) |
Total fat (kg), media (±DE) | 11,36 (8,9) |
Total Lean (kg), media (±DE) | 26,1 (8,9) |
Total mass (kg), media (±DE) | 38,8 (16,7) |
MFI (%) media (±DE) | 7,5(5,3) |
MFFI (%) media (±DE) | 17,8 (3,8) |
P86 Hypovitaminosis D in juvenile idiopathic arthritis: prevalence and involved factors
Rocio Galindo Zavala1, Laura Martín Pedraz2, Esmeralda Núñez Cuadros1, Gisela Díaz-Cordovés Rego3, Antonio L. Urda Cardona2
1Paediatric Rheumatology, Universitary Regional Malaga Hospital, MALAGA, Spain; 2Paediatrics, Universitary Regional Malaga Hospital, MALAGA, Spain; 3Rheumatology, Universitary Regional Malaga Hospital, MALAGA, Spain
Correspondence: Rocio Galindo Zavala
PATIENTS` CHARACTERITICS (N = 76) | ||
---|---|---|
Gender (Male), | 23 (30,3) | |
Age (years), median (IR) n (%) | 10,83 (8,52-13,54) | |
25OH-Vitamin D (ng/mL), mean (+/-SD) | 34,04 ng/mL (8,90 ng/mL) | |
DISEASE CHARACTERISTICS (N = 76) | ||
JIA subtype, n (%) | Systemic | 9 (11,8) |
Oligoarticular | 47 (61,9) | |
Polyarticular | 20 (26,3) | |
Inflammatory activity duration (days), median (IR) | 385,0(246,75-761,25) | |
RECEIVED TREATMENTS (N = 76)* | ||
Systemic GC, n (%) | 61 (80,2) | |
Synthetic DMARDs treatment, n (%) | 39 (51,3) | |
Biological DMARDs treatment subtype, n(%) | Anti-TNFα | 15 (19,7) |
Anti-IL1 | 4 (5,2) | |
Anti-IL6 | 2 (2,6) |
P87 Neuropsychological assessment in juvenile idiopathic arthritis - Part I: cross-sectional study in a single Hungarian centre
Diana Garan1, Gyurgyinka Gergev1, Wouter Wijker2, Imre Bozi2, Tamás Constantin1
1Rheumatology, 2nd Department of Pediatrics Semmelweis University, Budapest, Hungary; 2Auxiliis-Pharma Kft., Budapest, Hungary
Correspondence: Diana Garan
P88 Characteristics of TNF inhibitor treatment in juvenile idiopathic arthritis - 2-year-follow-up in a Hungarian centre
Diana Garan, Anita P. Juhász, Andrea Ponyi, Tamás Constantin
Rheumatology, 2nd Department of Pediatrics Semmelweis University, Budapest, Hungary
Correspondence: Diana Garan
P89 Body composition measured by DEXA in children with juvenile idiopathic arthritis. do they have sarcopenia?
Pilar Guarnizo1,2,3, Sally Pino2,4, Adriana Diaz-Maldonado2,5,6, Juan Manuel Reyes2
1Fundacion Cardio Infantil, Bogota, Colombia; 2Care for Kids, Bogota, Colombia; 3Cayre, Bogota, Colombia; 4Hospital Universitario Infantil de San Jose, Bogota, Colombia; 5Hospital de La Misericordia, Bogota, Colombia; 6Instituto Roosevelt, Bogota, Colombia
Correspondence: Pilar Guarnizo
P90 Clinical TMJ involvement in JIA patients according to the ILAR categories : preliminary study in 137 children.
Severine Guillaume Czitrom, Gianpaolo de Filippo
Service de Medecine des Adolescents, Chu Bicetre, Kremlin-Bicetre, France
Correspondence: Severine Guillaume Czitrom
P91 MRP8/14 and conventional inflammatory markers explaining physician’s global assessment of disease activity in new-onset juvenile idiopathic arthritic patients
Paula Keskitalo1, Salla Kangas2, Paula Vähäsalo1
1Department of Children and Adolescents, University of Oulu, Oulu, Finland; 2Medical Research Center Oulu, Oulu University Hospital and PEDEGO Research Unit, University of Oulu, Oulu, Finland
Correspondence: Paula Keskitalo
B | 95% CI | P-value | R2
| |
---|---|---|---|---|
ESR | 0.358 | 0.194 – 0.523 | <0.001 | 18.3% |
CRP | 0.345 | 0.227 – 0.463 | <0.001 | 28.7% |
Leucocytes | 1.387 | 0.064 – 2.710 | 0.040 | 4.9% |
Neutrophils | 1.849 | -0.289 – 3.986 | 0.089 | 4% |
MRP8/14 in serum | 0.056 | 0.024 – 0.087 | 0.001 | 12.9% |
MRP8/14 in plasma | 0.075 | 0.056 – 0.094 | <0.001 | 47.8% |
P92 Chronic arthritis as the only manifestation of FMF in Armenian children
Gayane Khloyan
ARABKIR JMS ICAH, Yerevan, Armenia
P93 The efficacy of etanercept in non-systemic juvenile idiopathic arthritis in Saint-Petersburg: the preliminary data of 148 patients from biologic registry.
Mikhail M. Kostik, Irina Chikova, Eugenia Isupova, Margarita Dubko, Vera Masalova, Ludmila Snegireva, Ekaterina Gaidar, Olga Kalashnikova, Vyacheslav Chasnyk
Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Correspondence: Mikhail M. Kostik
Parameter | Baseline | End of study | p |
---|---|---|---|
Morning stiffness, minutes | 60.0 (30.0; 120.0) | 20.0 (10.0; 20.0) | 0.03 |
Global disease activity, mm | 48.0 (35.0; 68.0) | 0.0 (0.0; 28.0) | 0.000001 |
MD VAS, mm | 43.5 (30.0; 60.0) | 0.0 (0.0; 18.0) | 0.000001 |
Patient’s VAS, mm | 20.0 (10.0; 20.0) | 0.0 (0.0; 10.0) | 0.000001 |
Painful joints, n | 2.0 (1.0; 5.0) | 0.0 (0.0; 0.0) | 0.000001 |
Swollen joints, n | 4.0 (2.0; 11.0) | 0.0 (0.0; 0.0) | 0.000001 |
Joints with LOM, n | 4.0 (1.0; 9.0) | 0.0 (0.0; 0.0) | 0.000001 |
Active joints, n | 7.0 (3.0; 15.0) | 0.0 (0.0; 0.0) | 0.000001 |
CRP, mg/l | 1.9 (1.0; 5.5) | 0.5 (0.2; 1.3) | 0.000001 |
P94 The treatment of 40 polyarticular juvenile idiopathic arthritis children with tocilizumab: single center experience.
Mikhail M. Kostik, Irina Chikova, Eugenia Isupova, Margarita Dubko, Vera Masalova, Ludmila Snegireva, Ekaterina Gaidar, Olga Kalashnikova, Vyacheslav Chasnyk
Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Correspondence: Mikhail M. Kostik
P95 Atypical oligoarticular juvenile arthritis in children: elbow chronic monoarthritis
Aleksey Kozhevnikov1,2, Nina Pozdeeva1, Michael Konev1, Maxim Nikitin1, Anastasia Bryanskaya1, Evgeniy Prokopovich1, Konstantin Afonichev1, Gennadiy Novik2
1Orthopedic and rheumatology department, Federal state budget institution “The Turner Scientific and Research Institute for Children's Orthopedics”, Saint-Petersburg, Russian Federation; 2Pediatric department n.a. prof. I.M. Voroncov, Federal state budget institution of higher professional education “Saint-Petersburg State Pediatric Medical University”, Saint-Petersburg, Russian Federation
Correspondence: Aleksey Kozhevnikov
P96 Platelet microparticles level in juvenile idiopathic arthritis
Sathish Kumar, Naresh Kumar
Rheumatology, Department of Pediatrics, Christian Medical College, Vellore, India
Correspondence: Sathish Kumar
Miscellaneous rheumatic diseases
P97 The need for dedicated paediatric rheumatology services: retrospective review of a clinic service at Tygerberg Hospital, South Africa
Deepthi R. Abraham1, Monika M. Esser2
1Dept of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, NHLS Immunology Unit Tygerberg Hospital, Division Medical Microbiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; 2Department of Pathology, NHLS Immunology Unit Tygerberg Hospital, Division Medical Microbiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
Correspondence: Deepthi R. Abraham
P98 Raynaud phenomenon secondary to the use of illicit drugs
P99 Unilateral recurrent ear chondritis in spondylarthritis does not always progress to polychondritis
Laura Damian1,2, Simona Rednic2,3,4, Cristina Pamfil5,6, Linda Ghib3, Maria-Magdalena Tamas3, Siao-Pin Simon2,5, Calin Lazar7, Laura Muntean5, Alma Maniu3,8
1Rheumatology, Centre for Rare Musculoskeletal Autoimmune and Autoinflammatory Diseases, Cluj-Napoca, Romania; 2Emergency Clinical County Hospital, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; 4Centre for Rare Musculoskeletal Autoimmune and Autoinflammatory Diseases, Cluj-Napoca, Romania; 5Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; 6Centre for Rare Musculoskeletal Autoimmune and Autoinflammatory Diseases, Emergency Clinical County Hospital, Cluj-Napoca, Romania; 7Pediatrics, Emergency Clinical County Hospital, Cluj-Napoca, Romania; 8ENT, Emergency Clinical County Hospital, Cluj-Napoca, Romania
Correspondence: Laura Damian
P100 Evaluation of the dental and temporomandibular joint status in children with generalized joint hypermobility
Ferhat Demir1, Tamer Tüzüner2, Özgül Baygın2, Mukaddes Kalyoncu1
1Department of Pediatric Rheumatology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey; 2Department of Pediatric Dentistry, Karadeniz Technical University Faculty of Dentistry, Trabzon, Turkey
Correspondence: Ferhat Demir
GJH group | Control group | p | |
---|---|---|---|
Age (median (min-max)) | 8 (5-17) | 9 (5-17) | 0.43* |
Gender (M/F) | 36/26 | 36/26 | 0.57#
|
VPI positivity (%) | 88.7 | 74.2 | 0.03#
|
GBI positivity (%) | 64.5 | 45.2 | 0.02#
|
DMFT score (median(min-max)) | 0.062 (0-0.23) | 0.080 (0-0.23) | 0.27* |
MT positivity (%) | 3.2% | 1.6% | 0.50#
|
TMD positivity (%) | 48.4% | 14.5% | <0.001#
|
P101 Successful treatment of pediatric IGG4 related ophthalmic disease with mycophenolate mofetil: case report and a review of the pediatric autoimmune dacryoadenitis literature
Talia Diaz, Yuridiana Ramirez, Sofia Osorio, Maria Teresa Braña, Luis Aparicio, Andres Rodriguez, Enrique Faugier, Rocio Maldonado
Pediatric Rheumatology, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico
Correspondence: Talia Diaz
P102 Rheumatic fever and post-streptococcal arthritis in a tertiary hospital from Paraguay.
Jorge Garcete1, Luz Galeano1, Carla Montiel2, Dong Chin2, Maria del Carmen Cabrera2, Milagros Vargas Peña2, Carlos Verón2, María Lezcano3, Alicia Aldana3, Ana Campuzano de Rolón1, Zoilo Morel Ayala4
1Pediatric Service, Hospital de Clinicas. Facultad de Ciencias Medicas.Universidad Nacional de Asuncion., San Lorenzo, Paraguay; 2Pediatric Cardiology, Hospital de Clinicas. Facultad de Ciencias Medicas.Universidad Nacional de Asuncion., San Lorenzo, Paraguay; 3Pediatric Neurology, Hospital de Clinicas. Facultad de Ciencias Medicas.Universidad Nacional de Asuncion., San Lorenzo, Paraguay; 4Pediatric Rheumatology, Hospital de Clinicas. Facultad de Ciencias Medicas.Universidad Nacional de Asuncion., San Lorenzo, Paraguay
Correspondence: Jorge Garcete
P103 Immunoglobulin therapy in the treatment of cerebral consequences of neonatal lupus erythematosus
P104 Validaty and reliability study for the Korean version of the haemophilia activity list in pediatric and adult patients with haemophilic arthropathy
Seonghoon Park, Hwajeong Lee, Jung-Yoon Choe
Department of mediciane, Catholic university of Daegu School of medicine, Daegu, Korea, Republic Of
Correspondence: Seonghoon Park
P105 Inflammatory pseudotumor: T helper cell subtypes and relation to IGG4-related disease?
Erdal Sag1, Gulsev Kale2, Beril Talim2
1Pediatric Basic Sciences, Pediatric Autoinflammatory Disease Programme, Hacettepe University Faculty of Medicine, Institution of Child Health, Ankara, Turkey; 2Department of Pediatrics, Pathology Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: Erdal Sag
P106 Hyperbaric oxygen therapy in a livedoid vasculopathy: a case report
Nihal Sahin1, Aysenur Pac Kisaarslan1, Sümeyra Ozdemir Cicek1, Betül Sözeri2, Mehmet E. Akcin3, Zubeyde Gunduz1, Ruhan Dusunsel1, Muammer H. Poyrazoglu1
1Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey 2Pediatric Rheumatology, Umraniye Research and Training Hospital, İstanbul, Turkey 3Underwater and Hyperbaric Medicine, Kayseri Research and Training Hospital, Kayseri, Turkey
Correspondence: Nihal Sahin
P107 Echocardiographic findings in children with osteogenesis imperfecta
Shahrzad Fallah1, Mohammad Reza Alaee2, Reza Shiari3, Saeed Mojtahed zadeh2, Behnam Sobouti4
1pediatrician, Shahid Beheshti Univesity of Medical Sciences Tehran, Iran, Islamic Republic Of’; 2Pediatric Cardiologist, Shahid Beheshti Univesity of Medical Sciences Tehran, Iran, Islamic Republic Of; 3Pediatric Rheumatology, Shahid Beheshti Univesity of Medical Sciences Tehran, Iran, Islamic Republic Of; 4pediatrician, Iran Medical Universuty, Tehran, Iran, Islamic Republic Of
Correspondence: Reza Shiari
P108 Acid ceramidase deficiency (Farber disease) causes symptoms resembling JIA and is likely underdiagnosed: we present a unique cross-sectional natural history study design to address the lack of clinical data on this rare disease
Alexander Solyom1, Boris Hügle2, Dustin Tetzl3, Edward H. Schuchman4
1Enzyvant, Basel, Switzerland; 2German Center for Pediatric Rheumatology, Garmisch-Partenkirchen, Germany; 3Enzyvant, New York, NY, United States; 4Genetic and Genomic Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY, United States
Correspondence: Alexander Solyom
P109 Involving patients, parents and carers in paediatric rheumatology research: best practices examples from lay representatives of the United Kingdom's clinical studies group
Simon Robert Stones1,2, Catherine Wright2,3 on behalf of Lay/Consumer CSG Representatives
1School of Healthcare, University of Leeds, Leeds, United Kingdom; 2Paediatric Rheumatology CSG, NIHR CRN: Children/Arthritis Research UK, Liverpool, United Kingdom; 3Arthritis Care Northern Ireland, Arthritis Care, Belfast, United Kingdom
Correspondence: Simon Robert Stones
P110 Defining the clinical impact of symptoms in a diverse population of patients with a rare disease: a qualitative research study in acid ceramidase deficiency (Farber disease)
Alexander Solyom1, Brendan Johnson2, Karoline Ehlert3, Dustin Tetzl4, Karin Coyne5
1Enzyvant, Basel, Switzerland; 2Roivant Sciences, Durham, NC, United States; 3University Medical Center, Greifswald, Germany; 4Enzyvant, New York, NY, United States; 5Evidera, Bethesda, MD, United States
Correspondence: Dustin Tetzl
P111 A novel homozygous mutation of gene WISP3 in progressive pseudorheumatoid dysplasia
P112 Association of juvenile-onset primary Sjögren syndrome with type I C2 deficiency
Erika Van Nieuwenhove1,2, Lien De Somer3, Carine Wouters3,4
1Center for Brain and Disease Research, VIB/KULeuven, Leuven, Belgium; 2Pediatrics, University of Leuven, Leuven, Belgium; 3Pediatric Rheumatology, University of Leuven, Leuven, Belgium; 4Department of microbiology and immunology, KULeuven, Leuven, Belgium
Correspondence: Erika Van Nieuwenhove
Psycho-social aspects and rehabilitation
P113 Introducing RAiISE - raising awareness of invisible illnesses in schools and education
Sophie Ainsworth1, Jenny Ainsworth1, Jennifer Preston2, Simon Stones1, Robyn Challinor1, Marie Rowe1
1RAiISE, Liverpool, United Kingdom; 2Patient and Public Involvement, Alder Hey Children's Foundation Trust, Liverpool, United Kingdom
Correspondence: Sophie Ainsworth
P114 Development and feasability of a shared management tool for school children with juvenile idiopathic arthritis
Jeannette H. Cappon1, Bianca Knoester1, Marion A. van Rossum2
1Paediatric Rehabilitation, Reade, center for Rheumatology and Rehabilitation, Amsterdam, Netherlands 2Paediatric Rheumatology, Amsterdam Rheumatology and Immunology Center |Reade, Amsterdam, Netherlands
Correspondence: Jeannette H. Cappon
P115 A smiling childhood: a social window for families with children affected by chronic rheumatics and rare pathologies
antonella celano, on behalf of apmar onlus, raffaella arnesano, annalisa sticchi, on behalf of apmar onlus and apmar onlus
Italian national Association people with rheumatic and rare diseases, Lecce, Italy
Correspondence: antonella celano
P116 Anxiety, depression, and parental perception of uncertainty among parents of children with juvenile idiopathic arthritis in Bogota, Colombia.
Adriana Diaz-Maldonado1,2,3, Sally Pino2,4, Pilar Guarnizo2,5,6, Juan Manuel Reyes2, Leonardo Ariza2
1Hospital de la Misericordia, Bogota, Colombia; 2Care for Kids, Bogota, Colombia; 3Instituto Roosevelt, Bogota, Colombia; 4Hospital San Jose Infantil, Bogota, Colombia; 5Fundacion Cardio Infantil, Bogota, Colombia; 6Cayre, Bogota, Colombia
Correspondence: Adriana Diaz-Maldonado
P117 Rehabilitation games for juvenile idiopathic arthritis. Focus on hand and wrist.
Michaela Foà1, Rocco M. Chiuri2, Antonella Petaccia1, Fabrizia Corona1, Pier L. Lanzi2, Giovanni Filocamo1
1Dipartimento della Donna, del Bambino e del Neonato, Fondazione Irccs Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 2Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, Italy
Correspondence: Michaela Foà
P118 Rehabilitation games for juvenile idiopathic arthritis. Focus on knee and ankle.
Amalia Lopopolo1, Mattia Giannotti2, Antonella Petaccia1, Fabrizia Corona1, Pier L. Lanzi2, Giovanni Filocamo1
1Dipartimento della Donna, del Bambino o del Neonato, Fondazione Irccs Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 2Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, Italy
Correspondence: Amalia Lopopolo
P119 Recurrent arthralgia or functional pain? Evaluation of psychological distress in Italian school students
margherita Lo Curto, Maria Cristina Maggio, Fabio Campisi, Giovanni Corsello
University Department Pro.Sa.M.I. “G. D’Alessandro”, University of Palermo, Palermo, Italy
Correspondence: Maria Cristina Maggio
P120 Posture and balance deficit in children with JIA: a pilot study
Antonino Patti1, Giovanni Corsello2, Antonino Bianco1, Giuseppe Messina1, Angelo Iovane1, Antonio Palma1, Jessica Brusa3, Maria Cristina Maggio2
1Department of Psychology and Educational Science, University of Palermo, Palermo, Italy; 2University Department Pro.Sa.M.I. “G. D’Alessandro”, University of Palermo, Palermo, Italy; 3Posturalab Italia, Palermo, Posturalab Italia, Palermo, Palermo, Italy
Correspondence: Maria Cristina Maggio
P121 Improved transitional process by nurse guided transition program
Karina Mördrup, Anna Vermé
Pediatric Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Correspondence: Karina Mördrup
P122 Transition in rheumatology- 5 year experience
Marija Šenjug Perica1, Miroslav Mayer2, Mandica Vidović3, Lovro Lamot3,4, Miroslav Harjaček3,4, Lana Tambić Bukovac1
1Department of Pediatric and Adolescent Rheumatology, Children’s Hospital Srebrnjak, Zagreb, Croatia; 2Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University Hospital Centre Zagreb, Zagreb, Croatia; 3Department of Pediatric and Adolescent Rheumatology, Clinical Hospital Centre Sisters of Charity, Zagreb, Croatia; 4University of Zagreb, School of Medicine, Zagreb, Croatia
Correspondence: Marija Šenjug Perica
P123 The psychomotor effect of an organized summer camp program on children with rheumatic diseases: a 5 year evaluation
Maria Stavrakidou, Kyriaki Spanidou, Polyxeni Pratsidou-Gertsi, Artemis Koutsonikoli, Florence Kanakoudi-Tsakalidou
First Dept of Pediatrics,Pediatric Immunology and Rheumatology Referral Center, Hippokration Hospital, Thessaloniki, Greece 2Asklepeio Physiotherapy Clinic, Thessaloniki, Greece
Correspondence: Maria Stavrakidou
Systemic lupus erythematosus
P124 Emerging role for the renal glomerular endothelial cells as potent inflammatory contributors in juvenile-onset lupus nephritis
Paraskevi Dimou1, Matthew Peak1,2, Angela Midgley1, Simon C. Satchell3, Rachael D. Wright1, Michael W. Beresford1,2
1Department of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom; 2Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom; 3Academic Renal Unit, University of Bristol, Bristol, United Kingdom
Correspondence: Paraskevi Dimou
ciGEnC treatment | Pro-inflammatory factors | Protein concentration (pg/ml)/surface expression Median/GeoMean Fluoresecence; IQR, n = 6) Untreated Stimulated | |
---|---|---|---|
TNF-α |
· GM-CSF | (0; 0-0) | (197.7; 189.7-272.3, P = 0.049) |
· MIP-1α | (208.5; 207-209) | (222.3; 221-223.3, P = 0.048) | |
· ICAM-1 | (247.5; 211.5-279) | (443; 353.3-472.3, P = 0.009) | |
IL-1β |
· IL-6 | (30.55; 16.9-108.5) | (3479; 1815-5243, P = 0.0004) |
· GM-CSF | (0; 0-0) | (950.5; 464.9-1128, P = 0.0004) | |
· TNF-α | (4.484; 3.717-4.383) | (10.60; 7.048-12.71, P = 0.011) | |
· MIP-1α | (208.5; 207-209) | (221.5; 215.8-225.8, P = 0.049) | |
IFN-γ |
· IL-10 | (0.514; 0.370-0.610) | (18.19; 15.69-19.77, P = 0.004) |
· TNF-α | (4.484; 3.717-4.383) | (8.381; 7.270-8.825, P = 0.029) | |
· IP-10 | (2.387; 2.279-3.688) | (3015; 2642-3114, P = 0.008) | |
IL-13 |
· sVCAM-1 | (191.8; 88.54-559.1) | (1539; 1033-1646, P = 0.022) |
Combined cytokine treatment |
· MCP-1 | (800.1; 446-1705) | (3755; 3359-3911, P = 0.008) |
· M-CSF | (192.4; 85.19-1427) | (3461; 2093-5098, P = 0.021) | |
· VCAM-1 | (59.60; 49.65-69.58) | (119; 85.13-163.3, P = 0.005) | |
LPS |
· IL-6 | (30.55; 16.9-108.5) | (3323; 2083-4886, P = 0.0007) |
· IL-10 | (0.514; 0.370-0.610) | (17.32; 9.014-20.25, P = 0.009) | |
· GM-CSF | (0; 0-0) | (312.2; 125.5-576.5, P = 0.017) | |
· IFN-γ | (0; 0-0) | (28.47; 12.14-40.44, P = 0.003) | |
· TNF-α | (4.484; 3.717-4.383) | (14.60; 10.38-20.15, P = 0.0005) | |
· IP-10 | (2.387; 2.279-3.688) | (2870; 1042-3147, P = 0.013) |
P125 Comparison of clinical and serological features of juvenile and adult-onset neuropsychiatric lupus in Spanish patients
Sandra Garrote Corral, Antía García Fernández, Walter A. Sifuentes Giraldo, Alina L. Boteanu, María L. Gámir Gámir, Antonio Zea Mendoza
Rheumatology, Ramon Y Cajal University Hospital, Madrid, Spain
Correspondence: Sandra Garrote Corral
Juvenile NPSLE | Adult NPSLE | p-value | |
---|---|---|---|
N° of patients | 28 (41%) | 41 (59%) | - |
Women:men | 20:8 | 39:2 | 0.0060* |
Time of disease (months) | 19.8 | 232.5 | 0.0001* |
NP manifestations at onset | 7 (25%) | 11 (27%) | 0.8651 |
Lupus nephritis | 16 (57%) | 9 (22%) | 0.0028* |
Anti-DNA ab (IU/ml) | 178.9 | 39.4 | 0.0005* |
ESR (mm/h) | 53.8 | 35.7 | 0.0199* |
C3 low (< 80 mg/dl) | 22 (79%) | 16 (39%) | 0.0012* |
C4 low (< 16 mg/dl) | 22 (79%) | 13 (32%) | 0.0001* |
P126 Cytokine profile and expression of STAT1 and STAT5 in peripheral blood in patients with childhood-onset systemic lupus erythematosus
Marija Holcar1, Aleš Goropevšek2, Tadej Avčin3
1Unit for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia ; 2Department for Laboratory Diagnostics, University Medical Centre Maribor, Maribor, Slovenia ; 3Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
Correspondence: Marija Holcar
P127 The expression of IFN receptor chains on naïve and primed neutrophils
Sophie Irwin1, Angela Midgley1, Matthew Peak2, Michael Beresford1,2
1Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom; 2NIHR, Alder Hey Clinical Research Facility, Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom
Correspondence: Sophie Irwin
P128 C1Q-deficiency lupus treated successfully with fresh frozen plasma in a sibling pair: first description of this novel therapy in paediatric patients
Rebecca A. James1, Yvonne Glackin1, Clarissa A. Pilkington1,2
1Department of Rheumatology, Great Ormond Street Hospital, London, United Kingdom 2UCL Institute of Child Health, University College London, London, United Kingdom
Correspondence: Rebecca A. James
P129 Childhood lupus glomerulonephritis outcome is associated with low C3 levels and anti-DNA antibodies at disease onset
Claudia S. Magalhaes1, Daniele F. Miguel1, Luciana G. Portasio1, Jose E. Corrente1, Glaucia F. Novak2, Beatriz Molinari2, Ana P. Sakamoto3, Rosa R. Pereira4, Teresa Terreri3, Eloisa Bonfa4, Lucia A. Campos2, Simone Appenzeller5, Claudio A. Len3, Clovis A. Silva2
1Sao Paulo State University (UNESP), Botucatu, Brazil 2University of Sao Paulo (ICr-USP), Sao Paulo, Brazil 3Sao Paulo Federal University (UNIFESP), Sao Paulo, Brazil 4University of Sao Paulo (USP), Sao Paulo, Brazil 5Campinas State University (UNICAMP), Campinas, Brazil
Correspondence: Claudia S. Magalhaes
P130 Decreased antibodies against rubella in previously vaccinated treatment naïve-JSLE patients: a prospective case control study
Despoina Maritsi1, Olga Vougiouka1, Margarita Onoufriou2, Susan Coffin3, Maria Tsolia1
1Second Department of Paediatrics, Medical Faculty, University of Athens, Athens, Greece, 2Pediatrics, "Archbishop MAkarios III" Children' Hospital, Nicosia, Cyprus, 3Infectious Diseases Department, Children's Hospital of Philadelphia, Philadelphia, PA, United States
Correspondence: Despoina Maritsi
Parameters | SLE group | Control group | P value |
---|---|---|---|
Study sample, n | 21 | 76 | 0.9* |
Age, years, mean (SD) | 13.3 (2.3) | 13 (2.7) | 0.8* |
Gender n (%) | |||
female | 20 (95%) | 72 (95%) | 0.83+ |
male | 1 (5%) | 4 (5%) | |
Steroids (21/21) | - | ||
- · mean dose | 10 mg | NA | |
- · mean duration of treatment | 17 months | ||
HCQ (21/21) | |||
- · mean dose | 200 mg | ||
- · mean duration of treatment | 36 months | ||
Azathioprine (9/21) | |||
- · mean dose | 75 mg | ||
- · mean duration of treatment | 18 months | ||
SLEDAI score | |||
- · Enrolment | 7 | ||
- · 1 year | 1 | ||
- · 3 years | 0 | ||
Seroprotection rate at diagnosis (%) | 95 | 98 | 0.4+ |
Seroprotection rate at 1 year (%) | 92 | 97 | 0.1+ |
Seroprotection rate at 3 years (%) | 89 | 96 | 0.04+ |
Mean IgG titers at diagnosis, mIU/ml | 432 | 590 | < 0.01* |
Mean IgG titers at 1 year, mIU/ml | 340 | 554 | < 0.01* |
Mean IgG titers at 3 years, mIU/ml | 298 | 468 | < 0.01* |
P131 Features of 1,555 childhood-onset lupus in three groups based on distinct time intervals to disease diagnosis: a Brazilian multicenter study
Glaucia V. Novak1, Beatriz C. Molinari1, Ana P. Sakamoto2, Maria T. Terreri2, Rosa M. Pereira3, Claudia Saad-Magalhães4, Nadia E. Aikawa3, Lucia M. Campos1, Claudio A. Len2, Simone Appenzeller5, Virgínia P. Ferriani6, Marco F. Silva7, Sheila K. Oliveira8, Aline G. Islabão9, Flávio R. Sztajnbok10, Luciana B. Paim11, Cássia M. Barbosa12, Maria C. Santos13, Blanca E. Bica14, Evaldo G. Sena15, Ana J. Moraes16, Ana M. Rolim17, Paulo F. Spelling18, Iloite M. Scheibel19, André S. Cavalcanti20, Erica N. Matos21, Teresa C. Robazzi22, Luciano J. Guimarães23, Flávia P. Santos24, Cynthia T. Silva25, Eloisa Bonfá3, Clovis A. Silva1
1Pediatric Rheumatology Division, CHILDREN’S INSTITUTE, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, São Paulo, Brazil 2Pediatric Rheumatology Division, Federal University of São Paulo (UNIFESP), São Paulo, Brazil 3Rheumatology Division, HOSPITAL DAS CLINICAS HCFMUSP, FACULDADE DE MEDICINA, UNIVERSIDADE DE SAO PAULO, São Paulo, Brazil 4Pediatric Rheumatology Division, Sao Paulo State University (UNESP), Botucatu, Brazil 5Pediatric Rheumatology Division, State University of Campinas (UNICAMP), Campinas, Brazil 6Pediatric Rheumatology Division, University of São Paulo (FMUSP-Ribeirão Preto), Ribeirão Preto, Brazil 7Pediatric Rheumatology Division, Hospital Geral de Fortaleza, Fortaleza, Brazil 8Pediatric Rheumatology Division, Rio de Janeiro Federal University (IPPMG-UFRJ), Rio de Janeiro, Brazil 9Pediatric Rheumatology Division, Hospital Jose Alencar, Brasilia, Brazil 10Pediatric Rheumatology Division, Pedro Ernesto University Hospital, Rio de Janeiro, Brazil 11Pediatric Rheumatology Division, Albert Sabin Hospital, Fortaleza, Brazil 12Pediatric Rheumatology Division, Hospital Darcy Vargas, São Paulo, Brazil 13Pediatric Rheumatology Division, Santa Casa de São Paulo, São Paulo, Brazil 14Rheumatology Division, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil 15Pediatric Rheumatology Division, Lauro Vanderley University Hospital, João Pessoa, Brazil 16Pediatric Rheumatology Division, Federal University of Pará, Pará, Brazil 17Pediatric Rheumatology Division, Obras Sociais Irmã Dulce, Salvador, Brazil 18Pediatric Rheumatology Division, Hospital Evangélico de Curitiba, Curitiba, Brazil 19Pediatric Rheumatology Division, Hospital Conceição, Porto Alegre, Brazil 20Pediatric Rheumatology Division, Federal University of Pernambuco, Recife, Brazil 21Pediatric Rheumatology Division, Federal University of Mato Grosso do Sul, Campo Grande, Brazil 22Pediatric Rheumatology Division, Federal University of Bahia, Salvador, Brazil 23Pediatric Rheumatology Division, University of Brasilia, Brasilia, Brazil 24Pediatric Rheumatology Division, Federal University of Minas Gerais, Belo Horizonte, Brazil 25Pediatric Rheumatology Division, Hospital Municipal Piedade, Rio de Janeiro, Brazil
Correspondence: Glaucia V. Novak
P132 Adult outcomes in a large cohort of childhood-onset SLE patients: coping and resilience in relation to health-related quality of life - the CHILL-NL study
Radhevi A. S. Ramnath1, Noortje Groot1, 2, Ayse Kaynak1, Marc Bijl3, Radboud J.E. M. Dolhain4, Y.K. O. Teng5, Els Zirkzee6, Karina de Leeuw7, Ruth Fritsch-Stork8, Irene Bultink9, Sylvia S. M. Kamphuis1 on behalf of the CHILL-NL study group
1Department of Pediatric Rheumatology, Sophia Children's Hospital - Erasmus University Medical Center, Rotterdam, Netherlands 2Department of Pediatric Immunology, Wilhelmina Children's Hospital - University Medical Center Utrecht, Utrecht, Netherlands 3Department of Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands 4Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands 6Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands 7Department of Rheumatology and Clinical Immunology, University Medical Center, Groningen, Netherlands 8Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands 9Amsterdam Rheumatology and Immunology Center, Location VUmc, Amsterdam, Netherlands
Correspondence: Radhevi A. S. Ramnath
P133 Understanding the immunopathogenesis of juvenile-onset SLE using immune and metabolic phenotyping
George Robinson1,2, Marsilio Adriani1, Ines Pineda Torra3, Yiannis Ioannou2, Elizabeth Jury1 and Jury Group
1Rheumatology, University college london, London, United Kingdom 2Centre for Adolescent Rheumatology, University college london, London, United Kingdom 3Clinical Pharmacology, University college london, London, United Kingdom
Correspondence: George Robinson
P134 Hepatitis a virus vaccination in juvenile-onset systemic lupus erythematosus
Sevinc Mertoglu1, Sezgin Sahin1, Omer F. Beser2, Amra Adrovic1, Pelin Yuksel3, Soner Sazak4, Bekir S. Kocazeybek3, Ozgur Kasapcopur1
1Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey 2Pediatric gastroenterology, Okmeydani Education and Training Hospital, Istanbul, Turkey 3Microbiology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey 4Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey
Correspondence: Sezgin Sahin
P135 Microangiopathy in childhood-onset systemic lupus erythematosus, a detailed further quantitative analysis of capillaroscopy abnormalities
Dieneke Schonenberg-Meinema1,2, J.M. vd Berg1, Amara Nassar-Sheikh-Rashid1, Godelieve de Bree3, A.E. Hak4, Marieke van Onna4, Karin Melsens5, Maurizio Cutolo6, T.W. Kuijpers1, Vanessa Smith5,7 and EULAR study group on microcirculation in rheumatic diseases
1Department of Pediatric Hematology, Immunology, Rheumatology and Infectious Diseases, Emma Children’s Hospital, Academical Medical Center, Amsterdam, Netherlands 2Department of Pediatric Hematology, Immunology, Rheumatology and Infectious Diseases, Emma Children’s Hospital, Academical Medical Center (AMC), Amsterdam, Netherlands, 3Department of Infectious Diseases, 4Department of Clinical Immunology and Rheumatology, Academical medical center, Amsterdam, Netherlands, 5Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 6Research Laboratory and Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy, 7Faculty of Internal Medicine, Ghent University, Ghent, Belgium
Correspondence: Dieneke Schonenberg-Meinema
P136 Timing of intravenous cyclophosphamide and long-term outcome in children with proliferative lupus nephritis
Tetsuya Tsuchida1, Asami Ohara1, Kenichi Nishimura1, Tomo Nozawa1, Ryoki Hara1, Shuichi Ito1
1Department of Pediatrics, Yokohama City University Hospital, Yokohama, Japan
Correspondence: Tetsuya Tsuchida
P137 Sexual differences in TLR7 driven interferon alpha production may explain the increased prevalence of JSLE in females after puberty
Kate Webb1, Gary Butler2, Madhvi Menon3, Hannah Peckham1, Ania Radziszewska1, Lucy R. Wedderburn1, Yiannis Ioannou1
1Centre for Adolescent Rheumatology, UCL, London, United Kingdom 2Paediatric endocrinology, UCL, London, United Kingdom 3Medicine, UCL, London, United Kingdom
Correspondence: Kate Webb
Systemic lupus erythematosus and antiphospholipid syndrome
P138 Similarities and differences between childhood-onset and adult-onset systemic lupus erythematosus in sultanate of Oman
Asma Al Rasbi1, Rabab Sultan2, Nisreen Abdallah3, Juma Al Kaabi3, Reem Abdwani2
1SQU, Muscat, Oman 2Child Health, SQUH, Muscat, Oman 3Medicine, SQU, Muscat, Oman
Correspondence: Reem Abdwani
aSLE 139(62%) | cSLE 86 (38%) | P Value | |
---|---|---|---|
Cutanous | 17 (12.2%) | 0 (0.0%) | 0.004 |
Arthritis | 74 (53.2%) | 58 (67.4%) | 0.050 |
Renal | 27 (19.4%) | 42 (48.8%) | P < 0.0005 |
Hematologic | 62 (44.6%) | 19 (22.1%) | 0.001 |
Neurologic | 12 (8.6%) | 15 (17.4%) | 0.078 |
Pulmonary | 4 (2.9%) | 11 (12.8%) | 0.009 |
SLEDAI at disease onset (Mean ± SD) | 8.47 | 13.27 | P < 0.05 |
SLEDAI over disease course (Mean ± SD) | 11.77 | 16.34 | P < 0.05 |
P139 Neonatal lupus erythematosus: a 12-year retrospective study in Korea
Jong Gyun Ahn1, Dong Soo Kim1, Young Dae Kim2, Kwang Nam Kim3
1Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic Of 2Department of Pediatrics, Inje University School of Medicine, Seoul, Korea, Republic Of 3Department of Pediatrics, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea, Republic Of
Correspondence: Jong Gyun Ahn
P140 Analysis of MEFV gene sequence variants and association with clinical features and disease activity in juvenile systemic lupus erythematosus patients
Ayşe Zopçuk1, Nuray Aktay Ayaz1, Betül Sözeri2, Mustafa Çakan1, Şerife Gül Karadağ1, Ayşenur Paç Kısaarslan3, Zübeyde Gündüz3
1Pediatric Rheumatology, Kanuni Sultan Süleyman Research And Training Hospital, İstanbul, Turkey 2Pediatric Rheumatology, Ümraniye Research And Training Hospital, İstanbul, Turkey 3Pediatric Rheumatology, Erciyes University, Kayseri, Turkey
Correspondence: Nuray Aktay Ayaz
Mutation | n | Min | Max | Mean ± SD | Median | p | |
---|---|---|---|---|---|---|---|
Age of Diagnosis (Year) | No | 26 | 3 | 17 | 12,6 ± 3 | 13 | 0,79 |
Yes | 14 | 8 | 17 | 12,9 ± 2,8 | 13,5 | ||
Duration of disease (month) | No | 26 | 10 | 100 | 34,9 ± 19,8 | 31 | 0,69 |
Yes | 14 | 11 | 71 | 37,4 ± 16,8 | 42 | ||
SLICC | No | 26 | 0 | 3 | 0,4 ± 0,8 | 0 | 0,59 |
Yes | 14 | 0 | 2 | 0,5 ± 0,7 | 0 | ||
SLEDAI | No | 26 | 0 | 10 | 3,1 ± 3,2 | 2 | 0,62 |
Yes | 14 | 0 | 8 | 1,8 ± 2,5 | 1 |
P141 Epidemiology, clinical characteristics and therapy approaches of a retrospective cohort of pediatric systemic lupus erythematosus in a tertiary centre
Rosa M. Alcobendas, Sara Murias, Agustin Remesal, Amelia Munoz Calongue
Pediatric Rheumatology, university hospital La Paz, Madrid, Spain
Correspondence: Rosa M. Alcobendas
P142 Histological grading of lupus nephritis is related to early change in growth parameters.
Yuri A. Arguello1, Giovanni Filocamo1, Sofia Torreggiani1, Valentina Litta Modigliani1, Giani Marisa1, Giovanni Montini1
1Medicine and Surgery Faculty, Università degli Studi di Milano, Milan, Italy
Correspondence: Yuri A. Arguello
P143 Is abnormality of lipid profile associated with more severe histological findings at renal biopsy in children with lupus nephritis ?
Francesco Baldo1, Valentina Litta-Modignani1, Sofia Torreggiani1, Carlo Virginio Agostoni1, Marisa Giani1, Giovanni Montini1, Giovanni Filocamo1
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Correspondence: Francesco Baldo
T1 | T2 | |||
---|---|---|---|---|
Mean ± (standard deviation) | ||||
Mild | Severe | Mild | Severe | |
Albumin (mg/dl) | 3,4 (± 0,8) | 3,7 ± (0,5) | 4 ± (0,9) | 3,7 ± (0,6) |
Total cholesterol (mg/dl) | 203,5 (± 68,5) | 187,7 ± (55,5) | 197,2 ± (51,4) | 222,5 ± (52) |
HDL-cholesterol (mg/dl) | 57,4 (± 37,4) | 39,9 ± (16,2) | 69 ± (28,3) | 52,5 ± (11,4) |
LDL-cholesterol (mg/dl) | 102,6 (± 30,1) | 130,2 ± (32,5) | 127,5 ± (40,3) | 124,8 ± (33,5) |
Triglycerides (mg/dl) | 164,7 (± 116,2) | 178,5 ± (163,4) | 129 ± (39,3) | 172,1 ± (99) |
P144 Clinical and immunological characteristics of childhood-onset systemic lupus erythematosus patients treated with rituximab
Alina Lucica Boteanu, Maria Angeles Blazquez Cañamero, Adela Alia Jimenez, Sandra Garrote Corral, Maria Jesus García Villanueva, Mariluz Gamir Gamir
Rheumatology, University Hospital Ramon Y Cajal, Madrid, Spain
Correspondence: Alina Lucica Boteanu
P145 Panniculitis in childhood-onset systemic lupus erythematosus: a multicentric cohort study
Lucia M. Campos1, Mônica Verdier 2, Pedro Anuardo 2, Natali Gormezano 1, Ricardo Romiti 3, Nadia Aikawa 2, Rosa Pereira 2, Maria T. Terreri 4, Claudia Magalhães 5, Juliana Ferreira 1, Marco Silva 1, Mariana Ferriani 1, Ana P. Sakamoto 4, Virginia Ferriani 6, Maraísa Centeville 7, Juliana Sato 5, Maria C. Santos 8, Eloisa Bonfá 2, Clovis Silva 1
1Paediatric Rheumatology Unit, Children’s Institute, University of São Paulo, São Paulo, Brazil 2Rheumatology Department, University of São Paulo, São Paulo, Brazil 3Dermatology Department, University of São Paulo, São Paulo, Brazil 4Paediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil 5Paediatric Rheumatology Unit, Faculdade de Medicina de Botucatu, Botucatu, Brazil 6Paediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, São Paulo, Brazil 7Paediatric Rheumatology Unit, University of Campinas, Campinas, Brazil 8Paediatric Rheumatology Unit, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil
Correspondence: Lucia M. Campos
P146 Prevalence of ena and anti cardiolipin antibodies in different classes of lupus nephritis.
Giancarla Di Landro, Francesco Baldo, Valentina Litta Modignani, Marisa Giani, Giovanni Montini, Carlo Virginio Agostoni, Giovanni Filocamo
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Correspondence: Giancarla Di Landro
AUTOANTIBODIES | MILD | SEVERE | p value | ||
---|---|---|---|---|---|
ENA: | 7 | 63,63% | 6 | 50,00% | 0,509 |
anti-RNP | 3 | 27,27% | 2 | 18,18% | 0,611 |
anti-Sm | 2 | 18,18% | 3 | 27,27% | 0,611 |
anti-Ro/SS-A | 5 | 45,45% | 4 | 36,36% | 0,665 |
anti-La/SS-B | 1 | 9,09% | 3 | 27,27% | 0,269 |
Scl-70 | 1 | 9,09% | 1 | 9,09% | 1 |
Anti-nucleosome and anti-histone | 1 | 9,09% | 0 | 0 | NS |
LAC | 2 | 20,00% | 2 | 18,18% | 0,91 |
IgM and IgG aCL > 10 | 4 | 40,00% | 4 | 40,00% | 1 |
P147 Juvenile systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of Mexican children.
Sofia Osorio, Andrés Rodríguez, Rocio Maldonado, Enrique Faugier, Talia Diaz, Yuridiana Ramirez, Luis Aparicio, Maria Braña
Pediatric Rheumatology, Hospital Infantil de Mexico Federico Gomez, Ciudad de mexico, Mexico
Correspondence: Talia Diaz
P148 Neonatal lupus - case series of a tertiary hospital
Ana R. Teixeira 1, Raquel Ferreira1, 2, Mariana Rodrigues 3, 4, Francisca Aguiar 1, 2, Iva Brito 2, 5
1Faculty of Medicine, University of Porto, Porto, Portugal 2Rheumatology, Centro Hospitalar de São João, Porto, Portugal 3Pediatrics, Centro Hospitalar de São João, Porto, Portugal 4Pediatrics, Faculty of Medicine, University of Porto, Porto, Portugal 5Medicine, Faculty of Medicine, University of Porto, Porto, Portugal
Correspondence: Raquel Ferreira
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | |
---|---|---|---|---|---|---|---|---|
Gender | F | F | M | F | F | F | M | M |
Maternal history | SS | LES | LES | LES | SS | SS | SS, LES | SS |
Dermatological involvement | No | No | No | No | No | No | Yes | Yes |
Cardiac involvement | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
Other organs involvement | No | Yes | Yes | No | No | No | No | No |
Child's autoantibodies | NE | Anti-SSA and SSB | Anti-SSA | NE | NE | Anti-SSB | Anti-SSA and SSB | NE |
Maternal autoantibodies | Anti-SSA | Anti-SSA and SSB | Anti-SSA and SSB | Anti-SSA | Anti-SSA and SSB | Anti-SSA and SSB | Anti-SSA and SSB | Anti-SSA and SSB |
P149 Gender differences in systemic lupus erythematosus presentation and treatment at paediatric rheumatology department, Sofia, Bulgaria for a period of 4 years (2013-2017)
Margarita Ganeva, Stefan Stefanov, Albena Telcharova, Dimitrina Mihaylova, Vanya Kostova, Katya Temelkova, Tanya Andreeva
Paediatric Rheumatology, University Children's Hospital, Medical University Sofia, Sofia, Bulgaria
Correspondence: Margarita Ganeva
P150 Differences of the metabolome of autoimmune diseases
Anna E. A. Glaser1, Angela Midgley1, Helen L. Wright2, Marie M. Phelan3,4, Matthew Peak5, Michael W. Beresford1,5
1Department of Women’s and Children’s Health, University of Liverpool, Liverpool, United Kingdom 2Department of Biochemistry, University of Liverpool, Liverpool, United Kingdom 3Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom 4HLS Technology Directorate, University of Liverpool, Liverpool, United Kingdom 5Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
Correspondence: Anna E. A. Glaser
P151 Primary antiphospholipid syndrome in children – case series from Chennai, South India
P152 Novel urine biomarkers for the assessment of pediatric systemic lupus erythematosus nephritis
Artemis Koutsonikoli1, Maria Trachana1, Evangelia Farmaki1, Vasiliki Tzimouli1, Polyxeni Pratsidou-Gertsi1, Nikoleta Printza1, Alexandros Garyphallos2, Vasiliki Galanopoulou3, Florence Kanakoudi-Tsakalidou1, Fotios Papachristou1
1First Department of Pediatrics, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece 2Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece 3Department of Rheumatology, Papageorgiou Hospital, Thessaloniki, Greece
Correspondence: Artemis Koutsonikoli
Treatment
P153 Smart technologies to improve health outcomes in juvenile idiopathic arthritis
Andrea Coda1, Dean Sculley1, Derek Santos2, Xavier Girones3, Derek Smith4, Joshua Burns5, Keith Rome6, Jane Munro7, Davinder Singh-Grewal8
1School of Health Sciences, The University of Newcastle, Ourimbah, Australia, 2School of Health Sciences, Queen Margaret University, Edinburgh, United Kingdom, 3Faculty of Health Sciences, Manresa University, University of Vic-Central University of Catalonia, University of Barcelona), Manresa, Spain, 4School of Health Sciences, James Cook University, Townsville, Australia 5 Allied Health (Paediatrics), The Children’s Hospital at Westmead & the University of Sydney, Sydney, Australia, 6 Acting Director of Health & Research Rehabilitation Institute, AUT University, Auckland, New Zealand, 7 Head of Rheumatology Unit, Dept of General Medicine, Royal Children’s Hospital, Parkville - Victoria, Australia 8Paediatric Rheumatologists & Paediatrician Consultant, Sydney Children Hospitals Network & Clinical A/Prof- The University of Sydney, Sydney, Australia
Correspondence: Andrea Coda
P154 Reduced-dose rituximab in treatment of pediatric rheumatic diseases
Nadina E. Rubio-Perez, Fernando Garcia-Rodriguez, Marcia D. Torres-Made, Manuel E. de la O-Cavazos
Pediatric Rheumatology, Departamento de Pediatría, Hospital Universitario "Dr. José E. González", UANL, Monterrey, Mexico
Correspondence: Fernando Garcia-Rodriguez
P155 Etanercept (ENBREL®) treatment retention in the sub-population of pediatric patients from a retrospective cohort study using Canadian claims-level data
Majed Khraishi1, Brad Millson2, John Woolcott3, Heather Jones4, Lisa Marshall4
1Faculty of Medicine, Memorial University of Newfoundland, St. Johns, Canada; 2Health Access and Outcomes, QuintilesIMS, Kanata, Canada; 3Inflammation and Immunology, Global Outcomes and Evidence, Pfizer, Collegeville, PA, United States; 4Inflammation and Immunology, Global Medical Affairs, Pfizer, Collegeville, PA, United States
Correspondence: Majed Khraishi
Year | Tracked Patients, n | Retained Patients, n | Retention Rate, % |
P-Value |
---|---|---|---|---|
1 | 65 | 44 | 68 | |
2 | 41 | 33 | 80 | 0.1501 |
3 | 31 | 28 | 90 | 0.0166 |
4 | 28 | 25 | 89 | 0.0290 |
5 | 25 | 19 | 76 | 0.4411 |
6 | 18 | 15 | 83 | 0.1952 |
P156 A case report of a pediatric patient with orbital IGG4-related disease
Anna Kozlova, Vasiliy Burlakov, Dmitriy Abramov, Garik Sagoyan, Anna Shcherbina
Immunology, Federal State Budgetary Institution "National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev" of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Correspondence: Anna Kozlova
P157 Optimum serum adalimumab levels in juvenile idiopathic arthritis according to the response criteria
Berta Lopez1, M. Isabel Gonzalez1, Miguel Marti1, Lorena Martinez2, Silvia Gabriela Ceberio2, Inmaculada Calvo1
1Pediatric Rheumatology, Huip La Fe, Valencia, Spain; 2Pharmacology, Huip La Fe, Valencia, Spain
Correspondence: BERTA LOPEZ
P158 Efficacy of omalizumab treatment in a girl with autoinflammatory desease and chronic urticaria
Maria Cristina Maggio1, Anna Lucania2, Giovanni Corsello1
1University Department Pro.Sa.M.I. “G. D’Alessandro”, University of Palermo, Palermo, Italy; 2II Pediatric Unit,, “G. Di Cristina” Children Hospital, ARNAS, Palermo, Palermo, Italy
Correspondence: Maria Cristina Maggio
P159 The use of consequential biologic DMARDs in paediatric rheumatology
Joseph Mcallister1, Adam Clough2, Phil Riley1, Alice Chieng1
1Paediatric Rheumatology, Royal Manchester Childrens Hospital, Central Manchester University Hospitals, Manchester, United Kingdom; 2Pharmacy, Royal Manchester Childrens Hospital, Central Manchester University Hospitals, Manchester, United Kingdom
Correspondence: Joseph Mcallister
Results table | |||||||
---|---|---|---|---|---|---|---|
bDMARD | No. patients | No. treatment years | Observed no. infections | Infections per 100 patient years | Observed no. adverse events | Adverse events per 100 patient years | % changed for ongoing JIA or uveitis |
1st agent | 34 | 51.1 | 64 | 3.68 | 23 | 3.68 | 58.8% |
2nd agent | 34 | 77.8 | 76 | 2.87 | 12 | 0.45 | 70% |
3rd agent | 10 | 5.8 | 10 | 17.39 | 2 | 3.48 | 25% |
4th agent | 4 | 5.3 | 8 | 37.5 | 0 | 0 | - |
Total | 1680 | 158 |
Uveitis
P160 The persistence of ana positive in JIA patients and the risk of developing chronic anterior uveitis: a retrospective study
Alina Lucica Boteanu, Maria Llop Vilaltella, Maria Andreina Terán Tinedo, Maria Angeles Blazquez Cañamero, Mariluz Gamir Gamir
Rheumatology, University Hospital Ramon Y Cajal, Madrid, Spain
Correspondence: Alina Lucica Boteanu
P161 Uveitis associated with juvenile idiopathic arthritis: lower prevalence and unique clinical characteristics in Asian patients
Pauline Chan Ng, Lee Kean Lim, Elizabeth Youning Ang, Pei Ling Ooi
Khoo Teck Puat-National University Children’s Medical Institute, National University Hospital, Singapore, Singapore
Correspondence: Pauline Chan Ng
Patient | JIA subtype | Gender; Ethnicity | Age of uveitis diagnosis (years) | Uveitis diagnosis from JIA diagnosis (years) | Symptom onset to diagnosis (months) | Symptoms | Disease extent | Complication | Treatment |
---|---|---|---|---|---|---|---|---|---|
1 | ERA | Male; Indonesian | 9.2 | – 3.8 | 0.6 | Pain and redness | Bilateral; anterior | – | Topical steroids, Adalimumab |
2 | ERA | Male; Indonesian | 13.8 | 1.3 | 1.1 | Redness, blurring of vision, photophobia | Bilateral; anterior | Macular oedema | Topical and systemic steroids, MTX, Adalimumab |
3 | ERA | Male; Indian | 13.0 | 0 | 1.6 | Redness | Bilateral; anterior | – | Topical and systemic steroids, MTX, Adalimumab |
4 | Oligoarticular-extended | Male; Indian | 5.1 | 1.5 | 5.2 | Left eye ptosis | Left; panuveitis | Macular oedema, glaucoma, cataract | Topical and systemic steroids, MTX, Infliximab; cataract surgery; YAG laser |